US20210369937A1 - Integrated system for assessing wound exudates - Google Patents
Integrated system for assessing wound exudates Download PDFInfo
- Publication number
- US20210369937A1 US20210369937A1 US17/398,552 US202117398552A US2021369937A1 US 20210369937 A1 US20210369937 A1 US 20210369937A1 US 202117398552 A US202117398552 A US 202117398552A US 2021369937 A1 US2021369937 A1 US 2021369937A1
- Authority
- US
- United States
- Prior art keywords
- wound
- sensor
- processor
- wound exudate
- exudate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000416 exudates and transudate Anatomy 0.000 title claims abstract description 198
- 206010052428 Wound Diseases 0.000 claims abstract description 247
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 247
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 239000012530 fluid Substances 0.000 claims description 49
- 239000013598 vector Substances 0.000 claims description 32
- 238000005259 measurement Methods 0.000 claims description 23
- 230000003595 spectral effect Effects 0.000 claims description 18
- 239000000090 biomarker Substances 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 15
- 238000004891 communication Methods 0.000 claims description 12
- 230000033001 locomotion Effects 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 230000001143 conditioned effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 40
- 230000008569 process Effects 0.000 abstract description 30
- 238000009581 negative-pressure wound therapy Methods 0.000 abstract description 16
- 230000008859 change Effects 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000000740 bleeding effect Effects 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 235000014676 Phragmites communis Nutrition 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010183 spectrum analysis Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 238000004497 NIR spectroscopy Methods 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002803 maceration Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004377 microelectronic Methods 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229920000547 conjugated polymer Polymers 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229920001746 electroactive polymer Polymers 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14557—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases specially adapted to extracorporeal circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/73—Suction drainage systems comprising sensors or indicators for physical values
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/74—Suction control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/95—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with sensors for exudate composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/96—Suction control thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3389—Continuous level detection
Definitions
- NPWT negative pressure wound therapy
- a system for assessing wound exudate from the wound of a patient may include a system comprising a wound treatment device, detecting means for detecting one or more values of one or more physiological parameters of the wound exudate, analyzing means for analyzing the values of the one or more physiological parameters so as to obtain an assessment of the wound exudate, and providing means for providing treatment guidelines based on the assessment, in which the wound treatment device, the detecting means, the analyzing means, and the providing means are integrated.
- FIG. 1 is a functional block diagram representing components of a wound exudate system, in accordance with an embodiment of the present invention.
- FIG. 2 shows an embodiment of a wound exudate system integrated within an NPWT device, in accordance with an embodiment of the present invention.
- FIG. 3 is flow diagram of a wound assessment process, in accordance with an embodiment of the present invention.
- FIG. 4 depicts a cross-sectional view of a wound exudate system, in accordance with an embodiment of the present invention
- FIG. 5 depicts an embodiment of a wound exudate system containing multiple light sources and multiple detectors, in accordance with an embodiment of the present invention.
- FIG. 6 depicts a wound exudate system that contains a flow disruption element, in accordance with an embodiment of the present invention.
- FIG. 7 depicts a wound exudate system containing an inflow feature with a biomarker coating, in accordance with an embodiment of the present invention.
- FIG. 8 depicts a wound drain tube configured with a tortuous path, in accordance with an embodiment of the present invention.
- FIGS. 9 and 10 depict embodiments of a wound exudate system for pinching a wound drainage line, in accordance with an embodiment of the present invention.
- FIG. 11 depicts a wound exudate system with multiple actuators for pinching a wound drain line, in accordance with an embodiment of the present invention.
- FIG. 12 depicts an alternative embodiment of a wound exudate system having multiple pinching mechanisms disposed along opposing sides of a wound drain line, in accordance with an embodiment of the present invention.
- FIGS. 13 and 14 depict an alternate embodiment of a wound exudate system containing a spring loaded latch in a secured state and released state, respectively, in accordance with an embodiment of the present invention.
- FIGS. 15 and 16 depict a wound exudate system configured with a resistive heat break element in a not applied state and an applied state, respectively, in accordance with an embodiment of the present invention.
- FIG. 17 depicts an embodiment of a wound exudate system containing thin membranes with pressure sensors disposed thereon, in accordance with an embodiment of the present invention.
- FIG. 18 depicts a wound exudate system containing thermal mass sensors, in accordance with an embodiment of the present invention.
- FIG. 19 depicts a wound exudate system configured within a collection chamber, in accordance with an embodiment of the present invention.
- FIG. 20 depicts a graph showing different spectral intensities, in accordance with an embodiment of the present invention.
- FIG. 21 is a flow diagram of a process for spectral analysis of wound exudate, in accordance with an embodiment of the present invention.
- FIG. 22 is an exemplary two-dimensional vector map representing a range of wavelengths measured during spectral analysis of wound exudate, in accordance with an embodiment of the present invention.
- FIG. 23 is a spectral graph of the measurements of the map of FIG. 22 , in accordance with an embodiment of the present invention.
- FIG. 24 is an exemplary three-dimensional vector map representing a range of wavelengths measured during spectral analysis of wound exudate, in accordance with an embodiment of the present invention.
- FIG. 25 illustrates an alternative embodiment of a wound exudate system disposed within an ancillary collection chamber, in accordance with an embodiment of the present invention.
- FIG. 26 is a flow diagram illustrating an exemplary process for obtaining flow measurements of wound exudate measurements, in accordance with an embodiment of the present invention.
- FIG. 27 is a two-dimensional graph depicting flow rate measurements, in accordance with an embodiment of the present invention.
- FIG. 28 is a flow diagram illustrating the steps in a read and assess loop process, in accordance with an embodiment of the present invention.
- FIG. 29 is a flow diagram illustrating a process for obtaining readings of wound exudate, in accordance with an embodiment of the present invention.
- wound exudate system or “system”
- system allow for convenient assessment of wound exudates from a wound site and may provide real time quantitative and predictive functionality, as well as an integrated inline diagnostic solution. Also, the system may be integrated into a wound treatment device.
- FIG. 1 is a block diagram of an embodiment of a wound exudate system 1 , in accordance with the present invention.
- sensors or detectors 11 may detect and retrieve data representing the condition of a wound.
- This wound data may be transferred electronically via wired or wireless means 17 to one or more processors 15 .
- the processors may, among other things, predict wound state and other treatment solutions, based on the wound data.
- data may be stored in a memory 16 .
- Information from the processor(s) 15 may be transmitted to an output device 19 by any means known in the art, in order to inform or alert a user about the health or state of a wound.
- FIG. 2 depicts one embodiment of a wound exudate system 18 .
- the system 18 is generally in fluid communication with a wound 3 (and wound exudate) of a patient 5 .
- Fluid communication between the system 18 , and the wound 3 may be by any means known in the art, e.g., a wound drain 7 that is part of a wound therapy device 9 .
- the wound exudate system 18 may include one or more sensors or detectors 11 , which may be used to detect various parameters, including but not limited to temperature, pH, color, viscosity and tone. These parameters are useful indicators of present wound state, and may be used in accordance with aspects of the present invention to render viable treatment options.
- the wound exudate system may optionally employ one or more types of light sources 13 .
- the light sources 13 may emit varying wavelengths of light, depending on their programmed functionality. The wavelengths of light may be emitted through the wound exudate and may be altered depending on the characteristics of the exudate itself.
- the wavelengths may then be detected by the sensors or detectors 11 .
- the wavelengths detected by the sensors or detectors 11 may represent various conditions of the wound exudate being analyzed.
- the sensors or detectors 11 may transmit information representative of the detected wavelengths via electronic circuitry 17 , to one or more processors 15 integral within the wound exudate system 18 .
- the one or more processors 15 may be adapted to receive the detected wavelength data, and conduct various analyses by way of programmed processes.
- the processor(s) 15 may receive the wavelength data from the sensor(s) 11 , and use such data in appropriate process.
- a determination of the process can be any type of diagnosis or categorization of wound health or healing, as well as a prescribed treatment regimen.
- Various information including but not limited to historical data, processes, and vector maps may be stored in a memory 16 .
- the determination of the process may be communicated, wirelessly or via wired means, to be displayed on an onboard or external display 19 .
- the exudate system 18 may be integrated directly into the wound therapy device 9 .
- the processor 15 may be integrated into the wound therapy device, and the sensors, detectors and circuitry may be integral with a wound drain that is part of an active treatment device, or a bandage or dressing.
- the system 18 may detect the presence of blood in the exudates, as well as monitor and assess other physiological values relevant to wound exudates, such as flow rate/quantity, color, bacterial traces, temperature, pH and the like.
- FIG. 3 is a flow diagram illustrating an exemplary wound exudate system process 500 .
- the blocks in FIG. 3 are representative of various functions of a wound exudate system, which may be combined, omitted, added, or reordered as suitable.
- sensors detect and/or measure one or more parameters of the wound exudate.
- Measurement Data obtained in block S 501 is transmitted to and received by one or more processors in block S 503 .
- the processors then analyze the received data in block S 505 . Based on results of analyzing, determination(s) may be made in block S 507 regarding the measurements by the sensors. Those determinations, which may include a diagnosis or treatment guideline may then be outputted via an alarm or warning in block S 509 , or an output display in block S 510 .
- the wound exudates systems disclosed herein and illustrated in the attached drawings may contain various structural features.
- the system may be configured differently to attach to an existing wound therapy device, or be integrated directly into one of these devices.
- the structure of the system may also include sources of light for spectral analysis, as well as sensors or detectors for detecting the light emitted by these light sources. Detection of light at a particular wavelength after it has been emitted through wound exudate may indicate the value of a certain parameter of the exudate.
- the system may also include sensors for measuring non-spectral parameters such as temperature and pressure.
- FIG. 4 depicts an embodiment of a wound exudate system 28 integrated into an existing wound drain line.
- the system contains a light source 29 for emitting light of a certain wavelength(s) into the exudate.
- the system also contains a detector 30 for detecting and/or sensing the emitted wavelengths of light after it has passed through wound exudate. Amplitude of the detected wavelengths represent the spectral attributes of the exudates and may be indicative of wound state.
- FIG. 4 depicts an optical barrier 31 disposed on the exterior of a wound drainage line 32 .
- the optical barrier 31 is useful for avoiding ambient light from reaching the wound exudate. This increases the accuracy of the detection, as it avoids any artifacts that may be caused by light other than that emitted by the source 29 .
- FIG. 5 depicts another alternative embodiment of the present invention, in which the system may contain multiband sources of light, including a narrowband source 33 and a broadband source 34 .
- Multiple multiband detectors 35 may also be disposed within the system. Multiband sources and detectors may be useful for detecting various wavelengths of light and therefore different attributes of the exudates.
- the detectors 35 may be configured to remove unwanted ambient light and obtain more complete spectral information.
- an exudates system may be integrated within a central suction system.
- the exudates system may be associated and operated in tandem with an existing central suction system, so as to warn and shutdown flow from the wound site in the case of an adverse event.
- the exudates system may clamp the wound drainage line in the case of an adverse event.
- Such an embodiment may provide a safe and low cost alternative to existing NPWT devices in a hospital setting. This mechanism may be useful in preventing inadvertent hemorrhagic crises created by undetected bleeding.
- the central suction unit may be pre-configured with an integrated wound monitoring system as described herein.
- FIG. 6 depicts an alternative embodiment of a wound exudate system that contains a flow disruption element 41 in combination with one or more detectors 40 and 42 and a source 44 .
- the arrangement of the present embodiment may provide more accurate sensing, based on the deflection of the flow disruption element.
- an exudates system may comprise a fluid channel through which exudates may pass.
- the fluid channel may further comprise an obstruction located in the path of the exudates, as seen in FIG. 6 .
- a disturbance in the flow is created.
- the behavior of the flow in and around the disturbance may be useful for measuring parameters of the flow, such as viscosity, concentration and/or composition of solid matter, etc.
- the disturbance in the flow can also be used to better mix the exudate, which may be useful for improving measurement accuracy.
- Any signal variation between detectors 40 and 42 may be related to the flow disruption element. Viscosity may also be used to determine general water content of the exudates, as well as the presence of large molecules.
- a wound exudate system may also be configured with a flow drain arranged in a tortuous path 60 , as seen in FIG. 8 . This configuration may function to eliminate ambient light from the sensory region 59 .
- an exudate assessment system may also have structures and shaped tubes in the flow path to ensure that the fluid under analysis does not mix with previously collected exudates prior to being assessed, as seen in FIGS. 8, 19 and 25 .
- the exudates system may have a chamber or trap 98 , as seen in FIG. 19 , into which fluids can pool, or low so as to assist with obtaining more precise measurements regarding the physical state of the exudates. Measurements, such as flow rate may be taken of the pooled fluid, the flowing fluid, or both. This embodiment may be particularly useful for measuring the thermal mass of the exudate.
- the exudates system may also comprise a compartment to be filled by exudates leaving the wound site as seen in FIG. 19 .
- the compartment may be suitable for isolating exudates for analysis or to periodically weigh exudates removed from the wound site so as to assess the rate of fluid removed from the wound site over time.
- the compartment may include an automatic means for emptying when the fluid volume reaches a set level.
- the compartment may have an active system such as valves, to empty the compartment when the fluid reaches a set level.
- the exudates system may comprise one or more valves to direct and/or interrupt flow through the wound drain.
- the exudates system may draw off fluid for a sample without fully interrupting flow through the fluid line. The separated fluid as indicated in FIG. 19 , is analyzed within the line and allowed to remix further downstream.
- An alternative design may include a sampling port for taking a sample for analysis.
- the exudates system may be integrated along an inner or outer surface of a canister or arranged, so as to mate with a canister.
- the system may be arranged to detect the values of various physiological parameters of the exudates accumulated during use.
- the system may monitor and detect the weight, height, impedance, etc. of the exudates as it accumulates in the canister. Such information may be valuable for determining if an adverse event has occurred, such as the onset of bleeding. It may also be valuable for determining the overall rate of exudates removal from the wound site, thus providing predictive planning for canister changes, or even to assess wound progression from a highly exudating state to a superficially exudating state.
- Changes in the rate of exudates flowing from the wound site may be indicative of a change in the wound state.
- changes in the composition of the wound exudates may indicate a clinically relevant change in the wound state.
- Such changes in exudates removal rates may also be useful in determining how to most optimally change from one therapy to another.
- a relative change from a highly exudating wound to one of a superficially exudating wound may be useful to monitor.
- a transition from a highly exudating wound to a superficially exudating wound may provide useful information as to when a patient may be transferred from a more expensive to a less expensive therapy.
- An example of an expensive therapy is NPWT, while examples of lower cost therapies are moist wound dressings or bandages.
- the exudates system may comprise a sensor or series of sensors suitable for determining the values of the above properties of wound exudates.
- the exudates system may also comprise one or more disposable sensors for enabling contact based measurements of the exudates.
- sensor elements may comprise acoustic, photoacoustic, electrochemical, optical, and/or impedance spectroscopic elements arranged so as to monitor values of one or more parameters of the exudates.
- the sensor or sensors may be arranged so as to collect information through the outer film of a dressing or through the wall of a wound drainage line.
- the sensors may be temperature sensors, optical sensors, impedance sensor, electrochemical sensors (e.g.,: amperometric sensors), capacitive sensors, or the like.
- the exudates system may comprise any type of flow sensor known in the art for determining the quantity or rate of fluid removed from a wound site.
- the flow sensor may be of a contact or non-contact type.
- the sensor may be a level sensor, a load cell, a flow event timer, a droplet counter, a velocimeter or the like.
- the sensor may be a load cell, pressure head monitor (such as a manometer), a strain gauge, a turbine, a thermal mass sensor, pressure loss monitors, a tow line, or similar.
- Any physiological parameter of wound exudates can be assessed using embodiments of the present invention.
- Particular parameters of interest may include, flow of wound exudates, volume rate, pH, temperature, hemoglobin concentration, color and tone.
- the exudates system may evaluate exudates flow rates by measuring the rate at which a collection chamber fills, as seen for example in FIGS. 19 and 25 .
- the exudates system may comprise a combination of a load cell with a measurement chamber to measure flow rate and an accelerometer to monitor orientation of the measurement chamber with respect to the vertical axis, as seen in FIG. 19 . Combined signals from the sensors may be used to determine the correct flow rate of exudates from the wound site independent of the orientation of the exudates system.
- the exudates system may have a chamber or trap 98 , as seen in FIG. 19 , into which fluids 97 may pool, or flow so as to assist with obtaining more precise measurements regarding the physical state of the exudates. Measurements, such as flow rate may be taken of the pooled fluid, the flowing fluid, or both by sensors 101 . This embodiment may be particularly useful for measuring the thermal mass of the exudate.
- the exudates system may also comprise a compartment 98 to be filled by exudates leaving the wound site as seen in FIG. 19 .
- the compartment 98 may be suitable for isolating exudates for analysis or to periodically weigh exudates removed from the wound site so as to assess the rate of fluid removed from the wound site over time.
- the compartment may include an automatic means for emptying when the fluid volume reaches a set level.
- the compartment may have an active system such as valves 99 , to empty the compartment 98 when the fluid 97 reaches a set level. Fluid may enter the compartment 98 through an inflow tube 96 , and exit the compartment 98 , via an exit tube 103 .
- the exudates system may comprise one or more valves 99 to direct and/or interrupt flow through the wound drain.
- the exudates system may draw off fluid for a sample without fully interrupting flow through the fluid line. The separated fluid as indicated in FIG. 19 , is analyzed within the line and allowed to remix further downstream.
- An alternative design may include a sampling port for taking a sample for analysis.
- Table 1 depicts various flow rates and their potential clinical indications. By quantifying these flow rates, and assessing them together with the other physiological parameters discussed herein, an accurate prediction of wound health may be obtained.
- FIG. 25 is an alternative embodiment of the present invention depicting a wound exudate system and strain gauges disposed within an ancillary collection chamber. Such measurements may be taken by one or more sensors, including but not limited to strain gauges 236 , a capacitive level gauge 244 , optical gauge elements 242 , and electrical gauge elements 240 . Standard types of gauges for measuring weight or level are well known in the art. For example a strain gauge is based on a simple electrical circuit, wherein mechanical stress caused by change in weight causes the electrical resistance of the elements to change in proportion to the weight applied.
- a capacitance gauge reads a different level of capacitance between two points.
- the level of fluid 237 in the chamber e.g., the wound fluid
- the level of the fluid in the container may be determined.
- an optical gauge may use light to determine the distance between two points (e.g., the top of the canister and the fluid may indicate changes in the level of the fluid 237 .
- the system in this particular example may include a small reservoir 230 in fluid communication with a larger reservoir 232 , an inlet port 234 feeding into the small reservoir 230 .
- the small reservoir 230 was attached to the larger reservoir 232 with a flexible support 238 .
- a strain gauge based load cell 236 was applied to the flexible support in order to measure flexure of the support during use 238 .
- Saline was used to approximate the fluid under measurement during the study.
- the system was also equipped with electrical gauge elements 240 , optical gauge elements 242 , a capacitive level gauge 244 . Therefore, the example demonstrates that individually, or if necessary in combination, different sensor types may be used to determine flow rate.
- the signal detected the system was related to the weight of the small reservoir. This is in turn related to the time integral of the flow rate of fluid into the container. Thus the flow rate was able to be extracted from the reservoir weight signal.
- a valve 246 was used between the small reservoir and the large reservoir in order to drain and reset the reservoir when it became too full. The flow dynamics of this emptying process can be used to determine viscosity related information about the fluid under study.
- FIG. 26 depicts a process 260 that is further related to flow measurement of FIG. 19 and FIG. 25 .
- the process 260 includes (1) taking a flow reading in block S 251 ; (2) removing any movement artifacts in block S 252 (1); and (3) calculating a flow rate in block S 253 based on methods known in the art and, in particular, those disclosed herein. If the calculated flow rate is acceptable, measurements will continue to be taken. If the flow rate is not acceptable an alarm or alert is triggered in block S 254 .
- the flow rates calculated in process 260 can also be mapped in a graph as seen FIG. 27 .
- the spectral maps described here in various values along the flow rate map may indicate an onset of infection and/or bleeding, i.e., 262 .
- Exudate flow rate which may be measured by the methods described herein, or any of the methods known to those of ordinary skill in the art is a reliable predictor of wound health.
- flow rate values, and changes in flow rate values may be detected through various means and may also be useful in determining how to most optimally change from one therapy to another.
- a relative change from a highly exudating wound to one of a superficially exudating wound may be useful to monitor.
- a transition from a highly exudating wound to a superficially exudating wound may provide useful information as to when a patient can be transferred from a more expensive to a less expensive therapy.
- NPWT neurotrophic factor
- moist wound dressings or bandages An example of an expensive therapy is NPWT, while an example of a lower cost therapy is moist wound dressings or bandages.
- changes in the rate of exudates flowing from the wound site may be indicative of a change in the wound state.
- changes in the composition of the wound exudates may indicate a clinically relevant change in the wound state.
- color assessment of a disposable element within the device, or disposable electrodes within tube maybe possible. It may also be possible to map color profiles of exudates to pH. Several fluorescent nanoparticles systems can change color based on pH. In addition, a conjugated polymer could be used to do the same (redox potentials will change based on the pH of the local environment).
- Temperature is useful for assessing bleeding events as well as to monitor for infection. Core blood is generally warmer than the interstitial fluids in the dermis. In general, embodiments using a disposable metallic element for measuring temperature values, as well as embodiments with reusable probes are envisaged.
- near infrared spectroscopy/visible spectroscopy may be used to detect the values of oxygen in hemoglobin present in wound exudates.
- the presence of oxygen may indicate the presence of hemoglobin, and therefore blood.
- this could trigger an indicator, or cause one of the pinch mechanisms described herein to clamp a wound drain line to prevent further bleeding.
- this event would provide a caregiver with appropriate treatment guidelines.
- Tone and/or luminocity may be used to describe the color of the exudates. Changes in tone and/or luminocity may be indicative of changes in the physiological state of a wound and its stage of healing. A quantification system for evaluating the wideband absorption spectrum may also be useful for assessing the color and tone of the exudate.
- a wound system may include one or more laser diodes that provide very narrow wavelengths used to perform measurements.
- a spectral map and/or vector can be generated by using a single detector in combination with multiple laser diodes and/or one or more scanning laser diodes.
- a scanning laser diode can produce a modulated wavelength through modulation of the driving signals produced by the drive electronics. Such modulation makes for simplified removal of artifacts caused by ambient light interference, movement and the like.
- a method for quantitative, real time spectral detection and assessment may be a steady, pulsed or modulated near infrared spectroscopy or functional near infrared spectroscopy technique. It may use multiple wavelength spectroscopy and the like.
- a exudates system may include a color analysis system in combination with a white light source.
- a color analysis system may comprise one or more photodiodes in combination with one or more bandpass filters in order to provide separate responses for segments of the light spectrum.
- One or more outputs from each band are generated, with each output providing the spectral component of a vector.
- Output vectors can be mapped to exudates states, thereby creating vector maps useful for determining the state of the exudates and thus, statements about the physiological condition of the wound, as seen in FIGS. 22-24 .
- FIG. 20 is one example of an absorption map or tone map for analyzing different absorption wavelengths.
- a two-dimensional map shows absorption of a source spectrum 108 along a blue 104 , yellow 105 , red 106 , and NIR 107 wavelength.
- This particular example depicts broadband detection for the colors indicated.
- a single broadband detector could also be used.
- Particular values seen in an absorption map can be translated into a particular assessment of a wound state.
- a process performed by the processor may be encoded to signal an alarm or pinch a drain line if a particular tonal color reaches a certain level.
- FIG. 21 depicts a flow diagram of various operations performed to assess the color or tonal characteristics of a wound exudate.
- An initial block S 110 may obtain various spectral components.
- any ambient light may be removed in block S 112 to increase the accuracy of any spectral readings from the wound exudate.
- tone vectors are calculated in block S 114 from the readings obtained from block S 110 .
- Tone vectors may be calculated by any means known in the art. However, in preferred embodiments, the vectors may be calculated using the following equation:
- Equation 1 is a linear weighting equation that casts portions of the sensor spectrum (each portion indicated by a coordinate X i ) into an nth order vector space. Each portion of the spectrum is weighted by a scalar weighting parameter A i (in this example only, more generally the weighting parameters may be equations, or algorithms that better map responses into the vector space, adjust for subject parameters, as well as adjust for changes in ambient conditions).
- the relationship computed in the equation may be used to map readings from individual sensors, wavelengths, and/or spectral bands into the nth dimensional figures, as disclosed herein. This process may be done to essentially create a map of the input responses into a quantifiable space such that diagnostic information may be more readily extracted from the collection of input signals. So for example, delta maps into this Nth order space, regions of which may have statistically significant relationships to various disease states, contraindications for the existing therapy, etc. By correlating where patient data falls on the map, and examining the historical data and trending data, the technology can assist in decision making with regards to therapeutic decisions.
- tone vectors are then compared to a tone map block S 116 containing standard or acceptable tonal values.
- the tone vectors from block S 114 are compared to the accepted values in block S 116 . If any of those values fall short of or exceed the acceptable ranges from block S 116 , a predetermined action in block S 120 is performed.
- a programmed action may include, triggering an audible alarm from actuating one of the latch mechanisms described herein.
- luminocity and tone may be indicative of infection, bleeding or increased edema in a wound, all conditions requiring urgent attention.
- Certain embodiments of the present invention may compare and analyze detected tone and luminocity values with predetermined values of tone and luminocity to provide a patient or caregiver with valuable treatment guidelines (see FIGS. 22, 23, and 24 ). Values of these various parameters may be combined into vector maps.
- FIG. 22 is a two-dimensional vector map 200 based on a range of colors at a given luminocity 201 , measured from the wound exudate.
- Map 200 represents data points along the spectral graph 206 , as shown in FIG. 23 .
- Different locations on the vector map 200 may indicate the likelihood or actual occurrence of various events related to wound state. For example at location 202 a normal exudate trend may be indicated, while locations 203 and 204 may indicate suspected bleeding or a high probability of bleeding, respectively.
- Location 205 may indicate the presence of an actual bleeding event.
- Graph 206 in FIG. 23 represents a line graph of three individual spectral profiles over a given period of time.
- FIG. 24 is a three-dimensional vector map, similar to the two-dimensional map shown in FIG. 22 , which is based on a range of colors measured from the wound exudate. Spectral components of wound exudate translated into vectors, may be mapped in such a two or three-dimensional map. By increasing the number of color channels, and therefore the number of wavelengths able to be detected, the sensitivity and accuracy of the system can be improved.
- Various points along the vector map, whether two or three-dimensional may also indicate a trend of wound health. For example curve 220 may indicate an initial trend while curve 222 may indicate a slight progression towards infection. Curve 224 may indicate the actual onset of infection while curve 226 may indicate various regions with a probability of infection.
- Given points, (e.g., 227 and 228 ) in the vector map may indicate a certain wound state.
- a wound state may correspond to a prescribed treatment guideline.
- treatment guidelines may include, but are not limited to varying the settings of an NPWT, or closing off a wound drain. Presence of bacteria or other infection may necessitate administration of antibiotics to the patient.
- an exudate assessment system analyze values detected from a wound, and provide decision support for the user regarding treatment options, rather than just data presentation.
- the system of the present invention is capable of analyzing the values of the data obtained from the sensors and/or detectors. Once an analysis is conducted the system may provide an assessment of the wound, as well as treatment guidelines.
- Embodiments of methods and apparatuses according to the present invention may detect values of various parameters in real time, and perform analyzing processes as shown in FIGS. 28 and 29 . These analyzing processes provide not only real time detection, which gives a much more accurate and reliable assessment of the wound, but also gives real time treatment suggestions, as they evaluate the current state of a wound, and not exudate that has been sitting in a collection canister for an extended period of time.
- the exudates system may comprise processing components to perform various processes that provide or output a wound state condition or treatment option, which may include, among other things, microelectronic circuits such as discrete circuits, microcontrollers, microprocessors, ASICs, FPGAs or the like, to condition and analyze sensor data to meaningfully interpret the physiological parameters of the exudates.
- the processing components may be located integrally within the system so that the sensors, light sources and processing components are all contained within the same device. In an alternative embodiment, the processing components may be remotely located from the other parts of the system.
- the process performed for analysis are generally adaptive and may be based on, one or more of the following: an averaged one-dependence estimators (AODE), Kalman filters, Markov models, back propagation artificial neural networks, Baysian networks, basis functions, support vector machines, k-nearest neighbors algorithms, case-based reasoning, decision trees, Gaussian process regression, information fuzzy networks, regression analysis, self-organizing maps, logistic regression, time series models such as autoregression models, moving average models, autoregressive integrated moving average models, classification and regression trees, multivariate adaptive regression splines.
- the sensor data may be analyzed from multiple sources using sensor fusion approaches.
- the specific process may be evolved using supervised learning, unsupervised learning, and/or reinforcement learning approaches.
- the device may comprise associated power sources and the like to drive the onboard electronics (sensors, microelectronic circuits, communication elements).
- tone and luminocity values are analyzed in combination with temperature readings, flow rate and NIR readings, a comprehensive statement may be made about the actual state of the exudates.
- a clinically appropriate set of treatment guidelines may be delivered by the system, thus eliminating the need for the caregiver or patient to have to interpret large amounts of data and make a subjective determination.
- FIG. 28 is a flow diagram of an exemplary process to obtain and analyze parameter readings, as well as present and display warnings and treatment options.
- the process of FIG. 28 is also referred to as a read and assess loop.
- the wound monitoring system may be at a sleep state to reserve or reduce power consumption.
- the system may be “woken up” during a wake-up phase S 201 , in response to some input. This input may be any type of stimuli such as motion, or as a result of a timer.
- This input may be any type of stimuli such as motion, or as a result of a timer.
- the system will obtain parameter readings S 203 .
- the device may immediately return to a rest state in block S 222 . If this is the logic path followed by the device, the readings obtained in block S 203 may also be stored in a memory.
- the device may be conditioned and cleaned in block S 205 .
- the device In the first mode from wake up, the device may be in a loop where it simply wakes up takes a reading, potentially stores it and then rests, as already described. If instead of resetting, the device needs to switch modes to monitoring disturbances from block 207 it will need to activate a conditioning function, which may be there to obtain the raw signals from 207 and prepare them for analysis (e.g., converting from analog to digital signals depending on sensor type or other forms of data conversion/signal conditioning know in the art). It may also be necessary to clean the signals because many signals can have “noise” or spurious data which may need to be filtered out before processing in 209 .
- the device may be conditioned and cleaned in block S 205 .
- This cleaning step aids in obtaining an accurate reading and filtering out any extraneous data or artifacts.
- the readings obtained in block S 203 are converted to vectors and assigned a corresponding weight S 209 .
- the weighting of the various readings can be based on any factor known in the art. By way of representative example only, one parameter such as temperature may be given a higher weight than pH, or vice versa. Such weighting can be changed from patient to patient or as applied to the same patient. Such weighting may also be assigned based on historical weights of various parameters.
- the processor in block S 213 compares the vectorized and weighted values to a vector map. At this point, the processor analyzes the data, and makes a determination, based on the vector's location on a vector map, as to whether the value is in a safe region in block S 217 . What constitutes a safe region is also a parameter that may be predetermined and stored in a memory associated with the processor. If, it is determined in block S 217 A the readings are in a safe region but appear to be trending toward an unsafe region, the weights of those readings may be adjusted in block S 217 ( b ) to assign a higher priority to said values.
- the system makes a determination as to whether or not it is worth warning a user S 217 ( c ) of the trend toward an unsafe region. If based on predetermined values, the processor determines that it is in fact worth warning a user, then a warning is issued in block S 217 ( d ). If not, the system returns to the rest state in block S 222 for power minimizing consumption.
- the processor determines whether or not the unsafe reading is a new occurrence in block S 219 . If it is a new occurrence, the alert weight of the occurrence is increased in block S 220 . Once the alert weight is increased, the processor returns to the rest state S 222 . If the device or processor determines that the unsafe reading is not a new occurrence, a determination is made as to whether the alert weight is critical in block S 219 ( b ).
- the alert weight is merely increased in block S 220 and the device returns to rest state S 222 . If the alert weight is critical, the processor determines in block S 219 ( c ) which region of the vector map the value falls in and what type of condition is therefore indicated by the value of the readings. Based on the region and type of event detected at in block S 219 ( c ), an action is initiated in block S 219 ( d ). An action may be an alert, an alarm, a pinching of a wound drain, or any other type of event or warning, which aids the user in assessing or treating the wound.
- the device and/or processor will record the event in block S 219 ( f ) and return to rest S 222 . If the event has not been resolved, the action at block S 219 ( d ) will be repeated or sustained.
- FIG. 29 is a detailed logic diagram of operations performed in block S 203 .
- the processor or device “wakes up,” the sensors 301 are then powered up.
- parameter values may be obtained S 303 .
- parameters such as spectral content of the wound exudate S 303 ( a ), flow S 303 ( b ), temperature S 303 ( c ), biomarker detection S 303 ( d ), and viscosity (e) are detected and measured. While these parameters are illustrated in FIG. 29 , they are by way of representative example only and the current invention can be used to measure any parameter present in wound exudate.
- These values are then converted to digital signals in block S 305 , which may be done as a low power conversion to reduce power requirements.
- the processor in block S 309 performs a check for values that may be statistical outliers.
- the values may be stored in a memory to be incorporated into the historical data S 309 ( a ). If the sample is determined to be a good sample in block S 311 , the processor will perform a specific calibration S 313 to adjust to the specific present conditions. Once this adjustment is performed, the processor in block S 315 may perform the conditioning and cleaning similarly as in step S 207 . If the sample is determined by the processor in blocks to not be a good sample, the event is recorded in block S 311 ( a ). If the bad sample is a recurring problem, which may be detected by prior historical values, an error message is displayed to the user in block 311 ( c ). If the problem sample is not recurring, the processor returns to rest S 311 ( d ).
- the processor After the processor has determined the wound state and/or treatment information, that data may be provided or communicated to a user or patient.
- the system is capable of communicating or providing values and treatment guidelines to a user.
- the system is also capable of communication directly with a negative pressure wound therapy device in order to effectuate necessary changes.
- the system comprises means for alerting a patient or caregiver to the presence of an abnormal state, quantity, or condition of the exudates.
- it may comprise one or more lights, a display, a speaker, a vibrating element, or similar in order to communicate information to a patient or caregiver.
- the device may further include wireless communication capabilities so as to deliver relevant information about the wound exudates to the NPWT device.
- relevant information may include the presence of blood in the exudates, the presence of bacteria, a change in the absorption spectrum of the exudates, a change in the flow rate of the exudates, and the like.
- Results of the wound assessment may be displayed through any type of graphical user interface, monitor or other type of display. Results of wound assessment may also be conveyed to a clinician and/or patient by the use of indicators as seen. Indicators may be any visual indicators such as lights, or audible indicators such as buzzers or alarms, or a haptic communication device such as a vibration motor to alert the clinician or patient when a particular event has been detected.
- the exudates system may comprise a means for communicating via a network such a cellular network, a wireless personal area network (WPAN), wide area network (WAN), metropolitan area network (MAN), local area network (LAN), campus area network (CAN), virtual private network (VPN), internet, intranet or near-me area network (NAN).
- a network such as a cellular network, a wireless personal area network (WPAN), wide area network (WAN), metropolitan area network (MAN), local area network (LAN), campus area network (CAN), virtual private network (VPN), internet, intranet or near-me area network (NAN).
- WPAN wireless personal area network
- WAN wide area network
- MAN metropolitan area network
- LAN local area network
- CAN campus area network
- VPN virtual private network
- internet intranet or near-me area network (NAN).
- NAN near-me area network
- the exudates system may be arranged as a node in a network, thus providing an element in a ring, mesh star, fully connected, line, tree or bus network topology.
- the exudates system communicates relevant values and as a node in a mesh or star network topology.
- the exudates system may comprise means for interfacing with a local telecommunications network, such as a cellular network via a locally positioned mobile handset, a wireless node, a wireless modem, phone adaptor or the like.
- a local telecommunications network such as a cellular network via a locally positioned mobile handset, a wireless node, a wireless modem, phone adaptor or the like.
- the exudates system may communicate relevant information through the network using various protocols such as IrDA, Bluetooth, UWB, Z-WAVE, ANT, or ZigBee.
- the relevant information is sent via low power protocols such as Blue tooth low energy, ANT or ZigBee.
- the exudates system may comprise an integrated power switch such that power is automatically provided to the onboard microcircuitry as soon as the system, or a wound device with which the system is associated, is positioned so as to effectively assess exudates.
- the system may comprise a proximity sensor to awaken the system itself or wound device from sleep. The sleep function may be useful to reserve power during periods of nonuse.
- the system may include a wound dressing with fluorescent biomarkers as shown in FIG. 7 .
- Biomarkers 50 may be employed for detecting various conditions. Biomarkers 50 can be assessed by externally positioned optical sensors 52 , thus providing a non-contact way to assess exudates properties. The optical sensors 52 can use colorimetric analyses to read the biomarkers 50 and detect the presence, absence or quantity of a particular value of a physiological parameter.
- an optional light source 56 may be used to emit light into the wound exudate.
- optical sensors 52 may be located on the outer surface of an opaque, or optically transparent tube 54 .
- Biomarkers can change based on local pH, local impedance, local redox potentials, color, and can fluoresce based on certain criteria, all of which are known in the art. As they interact with the exudates they are useful to detect the presence or absence of certain biological materials.
- the exudates system may read, detect or assess the biomarkers through optical means (color change, fluorescence, etc.), or electrical means (pH, redox, impedance, etc.).
- the system may detect presence of an infection, including but not limited to methicillin resistant staphylococcus aureus (MRSA) or vancomycin resistant enterococci (VRE), to alert a patient at home that they need in-patient hospital treatment.
- MRSA methicillin resistant staphylococcus aureus
- VRE vancomycin resistant enterococci
- these various infections may be detected by assessing biomarkers integrated within the system, or by assessing the value of other physiological parameters, including but not limited to temperature.
- each process performed by the system can be done in a non-contact fashion such that the sensors and electronics supporting the sensors do not come into contact with the exudates. This allows the components of the system to be reused, as cross contamination is avoided, thus sparing the expense of having to use replaceable sensors with each use.
- Non-contact is defined herein as not having direct contact between the fluid under analysis, and the sensory elements.
- Thin membranes in the drainage lines can be used to sense pressure, temperature, etc. (see FIG. 17 ).
- FIG. 18 depicts an alternative embodiment of a wound exudate system, which contains pressure sensors.
- the wound exudate system may contain two sections adjacent to a wound drain 89 . Those two regions are indicated in FIG. 17 as 91 and 92 at the interface of the system and the drain where the wall thickness of the system is reduced.
- a thin membrane is disposed thereon (not shown). The thinner membrane allows pressure sensors to detect a pressure inside the drain at locations 91 a and 92 a.
- a pressure P 1 is assigned to a pressure reading at location 91 a and a second pressure P 2 is obtained for the pressure reading at location 92 a.
- the difference between these two pressure readings can be used to establish, for example, flow rate, viscosity.
- the configuration described above may be self-contained within a disposable shunt for placement over an existing wound drain line, or designed as an integral component of a wound drain line.
- FIG. 18 depicts an embodiment similar to that as seen in FIG. 17 .
- the embodiment depicted in FIG. 18 measures thermal mass vis-à-vis a microheating element disposed in each of recesses 93 and 94 . This embodiment may be useful to estimate flow rates along the wall of a wound drain line.
- the exudates system may comprise a means for pinching off, or otherwise closing a wound drainage line in the event of an anomaly (such as the presence of blood in the exudates).
- the device may comprise an actuator that may be deployed so as to squeeze the line during an adverse event.
- the actuator may be arranged such that it is forcefully retracted during normal operation and is released during an adverse event, thus clamping down onto a wound drain line and pinching off fluid flow.
- FIGS. 9-16 depict various control mechanisms for controlling or stopping the flow of any fluid from a wound.
- These control mechanisms may include pinch lines to control the flow of exudates upon detection of a certain physiological value.
- These pinch mechanisms may also be referred to herein as latches.
- Different types of latches may be activated by different mechanisms.
- the latch is an active material element that will change shape in response to a stimulus. Suitable active materials include shape memory alloys, electroactive polymers, piezoceramics, etc.
- the active material latch is designed such that it releases upon stimulation.
- the system may pinch the wound drainage line so as to force a fault (blocked line fault) on the NPWT device.
- the system need not have its own means for alerting the patient or caregiver of an adverse event, but rather may trigger an alarm that is present in existing NPWT devices to achieve this goal.
- a suitable latch is designed with an integrated resistive heating element 80 , a reed 81 and a disbondable fastened region 83 , as seen in FIG. 15 .
- the reed is deformed during manufacturing and bonded with the disbondable fastened region 83 in the deformed state.
- the reed is also bonded to an attachment point 84 , in which the bond is not broken.
- the latch system is designed such that fluid can flow through an adjacent channel when the reed is held to the disbondable region, but that fluid flow through the channel on fluid line 85 may be blocked when the reed is released 87 .
- the disbondable fastened region 83 melts, deforms, or vaporizes, causing the deformed reed to break away from the fastened region 83 .
- the reed bridges the fluid line 85 , as shown in FIG. 16 , preventing flow and optionally triggering a blockage alarm.
- Other alternative latch designs will be evident to someone skilled in the art.
- the wound drain may have a particular shape so as to maintain laminar flow of the exudate during suction, in addition to providing for an actuating means for pinching off a wound drain line in the event of an adverse event such as bleeding.
- Representative examples of this embodiment can be seen in FIGS. 9 and 10 .
- the mechanical elements present in this embodiment are comprised of a solenoid based pinch valve 65 .
- the pinched valve 65 of the present embodiment contains a coil magnet 66 and a coiled actuator magnet 67 .
- the pinched valve may be actuated to close or substantially narrow the interior wall of the wound drain 69 .
- This change of the channel width of the wound drain assists in detecting laminar to turbulent flow and may restrict flow for better analysis or measurement.
- the embodiment depicted in FIG. 9 may be combined with any of the other embodiments described herein, such as a flow disruption element 70 as shown in FIG. 10 .
- flow disruption element When flow disruption element is present, analysis and detection may take place along an analysis flow region 64 by sources 62 and detectors 63 .
- FIG. 12 depicts an alternative embodiment wherein multiple pinching actuators 73 are disposed on opposite sides of a wound drain line.
- the actuators 73 depicted in FIG. 12 can be activated in response to a stimulus, such as the presence of blood. In the event the actuators 73 are activated and pinch the drain line to prevent further bleeding.
- An alarm 74 can signal a blocked flow line.
- FIG. 13 depicts yet another embodiment of the present invention containing a spring loaded, resettable latch.
- the spring loaded latch Upon actuation, the spring loaded latch releases and causes the mechanism to pinch the wound drain line 79 in the event of the detection of some unwanted occurrence, such as bleeding, as shown in FIG. 14 .
- the spring loaded element 75 once actuated can be reset and the latch 77 may be re-secured, as shown in FIG. 13 .
- electronics and power sources necessary for operation may be contained on an external housing.
- the dressing component may be modified so as to easily integrate with the exudate assessment system.
- the dressing may have electrical traces as an interface.
- the electrical traces may be printed using electroconductive inks (Ag, AgCl, C, Ni, etc.), or formed via several available RFID techniques known in the art, and embedded for electrically interacting with the exudate assessment system.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
An integrated system for assessing wound exudates from the wound of a patient is described. The system may contain functionality to detect, process and report various wound parameters. The system also may make treatment determinations based on these findings. The system may detect one or more physiological values of the wound exudates from the wound of the patient. The system may means for comparing the one or more detected physiological values to predetermined physiological values in order to obtain a comparison result in real time. The system may include a processor 15 which provides an electronic signal based on a comparison result in which the electronic signal may correspond to guidelines for treating the wound 13. The system may be integrated with other wound treatment devices, such as negative pressure wound therapy devices (NPWT) 9.
Description
- This application is a continuation application of, and claims the priority benefit of, U.S. application Ser. No. 16/237,421, which was filed on Dec. 31, 2018, and which is a continuation application of U.S. application Ser. No. 13/992,637, which was filed on Jul. 26, 2013 and which issued as U.S. Pat. No. 10,207,031. U.S. application Ser. No. 13/992,637 is a national stage entry of International Application No. PCT/US2011/063781, which was filed on Dec. 7, 2011, and which claims priority to U.S. Provisional Patent App. Ser. No. 61/421,003, which was filed on Dec. 8, 2010. The disclosures of those applications are incorporated by reference herein in their entireties.
- There is a need to autonomously monitor and assess the negative pressure wound therapy (“NPWT”) process and to provide a mechanism to interrupt the NPWT therapy in cases where a contraindication develops in the patient during use. There is also a further need to improve upon certain features of NPWT devices, such as safety, functionality and intelligent, real time feedback.
- Current treatment protocols for assessing wound state involve the qualitative analysis by caregivers. Often, a caregiver may assess the condition of a wound by the way it looks or smells or the overall appearance of the exudates. Many times, however, the caregiver may not be assessing the wound regularly or quantitatively. Such assessment may only occur at daily or weekly intervals, for example. A disadvantage to this treatment protocol is that the assessment is of old exudates. The physiological parameters of these exudates may change over time, when compared to their original state in the wound. Color, microbes, oxygen, and temperature all change over time, so the assessment of the exudates at a time after they have been collected is not an accurate or reliable prediction of wound condition. Additionally, the flow of exudates may be a useful tool in wound assessment. Prior assessment techniques may not offer a viable solution for monitoring wound exudates flow.
- In accordance with an aspect of the invention, a system for assessing wound exudate from the wound of a patient may include a system comprising a wound treatment device, detecting means for detecting one or more values of one or more physiological parameters of the wound exudate, analyzing means for analyzing the values of the one or more physiological parameters so as to obtain an assessment of the wound exudate, and providing means for providing treatment guidelines based on the assessment, in which the wound treatment device, the detecting means, the analyzing means, and the providing means are integrated.
-
FIG. 1 is a functional block diagram representing components of a wound exudate system, in accordance with an embodiment of the present invention. -
FIG. 2 shows an embodiment of a wound exudate system integrated within an NPWT device, in accordance with an embodiment of the present invention. -
FIG. 3 is flow diagram of a wound assessment process, in accordance with an embodiment of the present invention. -
FIG. 4 depicts a cross-sectional view of a wound exudate system, in accordance with an embodiment of the present invention -
FIG. 5 depicts an embodiment of a wound exudate system containing multiple light sources and multiple detectors, in accordance with an embodiment of the present invention. -
FIG. 6 depicts a wound exudate system that contains a flow disruption element, in accordance with an embodiment of the present invention. -
FIG. 7 depicts a wound exudate system containing an inflow feature with a biomarker coating, in accordance with an embodiment of the present invention. -
FIG. 8 depicts a wound drain tube configured with a tortuous path, in accordance with an embodiment of the present invention. -
FIGS. 9 and 10 depict embodiments of a wound exudate system for pinching a wound drainage line, in accordance with an embodiment of the present invention. -
FIG. 11 depicts a wound exudate system with multiple actuators for pinching a wound drain line, in accordance with an embodiment of the present invention. -
FIG. 12 depicts an alternative embodiment of a wound exudate system having multiple pinching mechanisms disposed along opposing sides of a wound drain line, in accordance with an embodiment of the present invention. -
FIGS. 13 and 14 depict an alternate embodiment of a wound exudate system containing a spring loaded latch in a secured state and released state, respectively, in accordance with an embodiment of the present invention. -
FIGS. 15 and 16 depict a wound exudate system configured with a resistive heat break element in a not applied state and an applied state, respectively, in accordance with an embodiment of the present invention. -
FIG. 17 depicts an embodiment of a wound exudate system containing thin membranes with pressure sensors disposed thereon, in accordance with an embodiment of the present invention. -
FIG. 18 depicts a wound exudate system containing thermal mass sensors, in accordance with an embodiment of the present invention. -
FIG. 19 depicts a wound exudate system configured within a collection chamber, in accordance with an embodiment of the present invention. -
FIG. 20 depicts a graph showing different spectral intensities, in accordance with an embodiment of the present invention. -
FIG. 21 is a flow diagram of a process for spectral analysis of wound exudate, in accordance with an embodiment of the present invention. -
FIG. 22 is an exemplary two-dimensional vector map representing a range of wavelengths measured during spectral analysis of wound exudate, in accordance with an embodiment of the present invention. -
FIG. 23 is a spectral graph of the measurements of the map ofFIG. 22 , in accordance with an embodiment of the present invention. -
FIG. 24 is an exemplary three-dimensional vector map representing a range of wavelengths measured during spectral analysis of wound exudate, in accordance with an embodiment of the present invention. -
FIG. 25 illustrates an alternative embodiment of a wound exudate system disposed within an ancillary collection chamber, in accordance with an embodiment of the present invention. -
FIG. 26 is a flow diagram illustrating an exemplary process for obtaining flow measurements of wound exudate measurements, in accordance with an embodiment of the present invention. -
FIG. 27 is a two-dimensional graph depicting flow rate measurements, in accordance with an embodiment of the present invention. -
FIG. 28 is a flow diagram illustrating the steps in a read and assess loop process, in accordance with an embodiment of the present invention. -
FIG. 29 is a flow diagram illustrating a process for obtaining readings of wound exudate, in accordance with an embodiment of the present invention. - A system, apparatus and method for monitoring and assessing wound exudates are disclosed herein. The system and apparatus (“wound exudate system” or “system”) allow for convenient assessment of wound exudates from a wound site and may provide real time quantitative and predictive functionality, as well as an integrated inline diagnostic solution. Also, the system may be integrated into a wound treatment device.
- In addition, a system and method for collecting physiological data, and predicting wound healing outcomes based on trends of values of exudate flow rate and other characteristics are also disclosed.
-
FIG. 1 is a block diagram of an embodiment of awound exudate system 1, in accordance with the present invention. In this embodiment, sensors ordetectors 11 may detect and retrieve data representing the condition of a wound. This wound data may be transferred electronically via wired or wireless means 17 to one ormore processors 15. The processors may, among other things, predict wound state and other treatment solutions, based on the wound data. - Optionally, data may be stored in a
memory 16. Information from the processor(s) 15 may be transmitted to anoutput device 19 by any means known in the art, in order to inform or alert a user about the health or state of a wound. -
FIG. 2 depicts one embodiment of awound exudate system 18. In accordance with an aspect of the present invention, thesystem 18 is generally in fluid communication with a wound 3 (and wound exudate) of apatient 5. Fluid communication between thesystem 18, and thewound 3, may be by any means known in the art, e.g., awound drain 7 that is part of awound therapy device 9. - The
wound exudate system 18 may include one or more sensors ordetectors 11, which may be used to detect various parameters, including but not limited to temperature, pH, color, viscosity and tone. These parameters are useful indicators of present wound state, and may be used in accordance with aspects of the present invention to render viable treatment options. - The wound exudate system may optionally employ one or more types of
light sources 13. Thelight sources 13 may emit varying wavelengths of light, depending on their programmed functionality. The wavelengths of light may be emitted through the wound exudate and may be altered depending on the characteristics of the exudate itself. - The wavelengths may then be detected by the sensors or
detectors 11. The wavelengths detected by the sensors ordetectors 11 may represent various conditions of the wound exudate being analyzed. The sensors ordetectors 11 may transmit information representative of the detected wavelengths viaelectronic circuitry 17, to one ormore processors 15 integral within thewound exudate system 18. - The one or
more processors 15 may be adapted to receive the detected wavelength data, and conduct various analyses by way of programmed processes. The processor(s) 15 may receive the wavelength data from the sensor(s) 11, and use such data in appropriate process. A determination of the process can be any type of diagnosis or categorization of wound health or healing, as well as a prescribed treatment regimen. Various information including but not limited to historical data, processes, and vector maps may be stored in amemory 16. - The determination of the process may be communicated, wirelessly or via wired means, to be displayed on an onboard or
external display 19. As shown inFIG. 2 , theexudate system 18 may be integrated directly into thewound therapy device 9. In this configuration, theprocessor 15 may be integrated into the wound therapy device, and the sensors, detectors and circuitry may be integral with a wound drain that is part of an active treatment device, or a bandage or dressing. - The
system 18 may detect the presence of blood in the exudates, as well as monitor and assess other physiological values relevant to wound exudates, such as flow rate/quantity, color, bacterial traces, temperature, pH and the like. -
FIG. 3 is a flow diagram illustrating an exemplary woundexudate system process 500. The blocks inFIG. 3 are representative of various functions of a wound exudate system, which may be combined, omitted, added, or reordered as suitable. - In block S501, sensors detect and/or measure one or more parameters of the wound exudate. Measurement Data obtained in block S501 is transmitted to and received by one or more processors in block S503. The processors then analyze the received data in block S505. Based on results of analyzing, determination(s) may be made in block S507 regarding the measurements by the sensors. Those determinations, which may include a diagnosis or treatment guideline may then be outputted via an alarm or warning in block S509, or an output display in block S510.
- The wound exudates systems disclosed herein and illustrated in the attached drawings may contain various structural features. The system may be configured differently to attach to an existing wound therapy device, or be integrated directly into one of these devices. The structure of the system may also include sources of light for spectral analysis, as well as sensors or detectors for detecting the light emitted by these light sources. Detection of light at a particular wavelength after it has been emitted through wound exudate may indicate the value of a certain parameter of the exudate. The system may also include sensors for measuring non-spectral parameters such as temperature and pressure.
-
FIG. 4 depicts an embodiment of awound exudate system 28 integrated into an existing wound drain line. The system contains alight source 29 for emitting light of a certain wavelength(s) into the exudate. The system also contains adetector 30 for detecting and/or sensing the emitted wavelengths of light after it has passed through wound exudate. Amplitude of the detected wavelengths represent the spectral attributes of the exudates and may be indicative of wound state. - Additionally, the embodiment depicted by
FIG. 4 depicts anoptical barrier 31 disposed on the exterior of awound drainage line 32. Theoptical barrier 31 is useful for avoiding ambient light from reaching the wound exudate. This increases the accuracy of the detection, as it avoids any artifacts that may be caused by light other than that emitted by thesource 29. -
FIG. 5 depicts another alternative embodiment of the present invention, in which the system may contain multiband sources of light, including anarrowband source 33 and abroadband source 34. Multiplemultiband detectors 35 may also be disposed within the system. Multiband sources and detectors may be useful for detecting various wavelengths of light and therefore different attributes of the exudates. Thedetectors 35 may be configured to remove unwanted ambient light and obtain more complete spectral information. - In another embodiment, which may be suitable for use in hospital setting, an exudates system may be integrated within a central suction system. In this case, the exudates system may be associated and operated in tandem with an existing central suction system, so as to warn and shutdown flow from the wound site in the case of an adverse event. In this case, the exudates system may clamp the wound drainage line in the case of an adverse event. Such an embodiment may provide a safe and low cost alternative to existing NPWT devices in a hospital setting. This mechanism may be useful in preventing inadvertent hemorrhagic crises created by undetected bleeding. In this case, the central suction unit may be pre-configured with an integrated wound monitoring system as described herein.
-
FIG. 6 depicts an alternative embodiment of a wound exudate system that contains aflow disruption element 41 in combination with one ormore detectors source 44. The arrangement of the present embodiment may provide more accurate sensing, based on the deflection of the flow disruption element. - In one embodiment, an exudates system may comprise a fluid channel through which exudates may pass. In this case, the fluid channel may further comprise an obstruction located in the path of the exudates, as seen in
FIG. 6 . As exudates pass the obstruction, a disturbance in the flow is created. The behavior of the flow in and around the disturbance may be useful for measuring parameters of the flow, such as viscosity, concentration and/or composition of solid matter, etc. The disturbance in the flow can also be used to better mix the exudate, which may be useful for improving measurement accuracy. Any signal variation betweendetectors - A wound exudate system may also be configured with a flow drain arranged in a
tortuous path 60, as seen inFIG. 8 . This configuration may function to eliminate ambient light from thesensory region 59. - In another embodiment of the present invention, an exudate assessment system may also have structures and shaped tubes in the flow path to ensure that the fluid under analysis does not mix with previously collected exudates prior to being assessed, as seen in
FIGS. 8, 19 and 25 . - In yet another embodiment, the exudates system may have a chamber or
trap 98, as seen inFIG. 19 , into which fluids can pool, or low so as to assist with obtaining more precise measurements regarding the physical state of the exudates. Measurements, such as flow rate may be taken of the pooled fluid, the flowing fluid, or both. This embodiment may be particularly useful for measuring the thermal mass of the exudate. - The exudates system may also comprise a compartment to be filled by exudates leaving the wound site as seen in
FIG. 19 . In this embodiment, the compartment may be suitable for isolating exudates for analysis or to periodically weigh exudates removed from the wound site so as to assess the rate of fluid removed from the wound site over time. The compartment may include an automatic means for emptying when the fluid volume reaches a set level. Alternatively, the compartment may have an active system such as valves, to empty the compartment when the fluid reaches a set level. - In this embodiment, the exudates system may comprise one or more valves to direct and/or interrupt flow through the wound drain. In yet another embodiment, the exudates system may draw off fluid for a sample without fully interrupting flow through the fluid line. The separated fluid as indicated in
FIG. 19 , is analyzed within the line and allowed to remix further downstream. An alternative design may include a sampling port for taking a sample for analysis. - In an alternative embodiment, the exudates system may be integrated along an inner or outer surface of a canister or arranged, so as to mate with a canister. In this embodiment, the system may be arranged to detect the values of various physiological parameters of the exudates accumulated during use. In this case, the system may monitor and detect the weight, height, impedance, etc. of the exudates as it accumulates in the canister. Such information may be valuable for determining if an adverse event has occurred, such as the onset of bleeding. It may also be valuable for determining the overall rate of exudates removal from the wound site, thus providing predictive planning for canister changes, or even to assess wound progression from a highly exudating state to a superficially exudating state.
- Changes in the rate of exudates flowing from the wound site may be indicative of a change in the wound state. In another instance, changes in the composition of the wound exudates may indicate a clinically relevant change in the wound state. Such changes in exudates removal rates may also be useful in determining how to most optimally change from one therapy to another. In one instance, a relative change from a highly exudating wound to one of a superficially exudating wound may be useful to monitor. A transition from a highly exudating wound to a superficially exudating wound may provide useful information as to when a patient may be transferred from a more expensive to a less expensive therapy. An example of an expensive therapy is NPWT, while examples of lower cost therapies are moist wound dressings or bandages.
- The exudates system may comprise a sensor or series of sensors suitable for determining the values of the above properties of wound exudates.
- The exudates system may also comprise one or more disposable sensors for enabling contact based measurements of the exudates. Such sensor elements may comprise acoustic, photoacoustic, electrochemical, optical, and/or impedance spectroscopic elements arranged so as to monitor values of one or more parameters of the exudates.
- The sensor or sensors may be arranged so as to collect information through the outer film of a dressing or through the wall of a wound drainage line. The sensors may be temperature sensors, optical sensors, impedance sensor, electrochemical sensors (e.g.,: amperometric sensors), capacitive sensors, or the like.
- The exudates system may comprise any type of flow sensor known in the art for determining the quantity or rate of fluid removed from a wound site. The flow sensor may be of a contact or non-contact type. In the case of a non-contact type flow sensor, the sensor may be a level sensor, a load cell, a flow event timer, a droplet counter, a velocimeter or the like. In the case of a contact type flow sensor, the sensor may be a load cell, pressure head monitor (such as a manometer), a strain gauge, a turbine, a thermal mass sensor, pressure loss monitors, a tow line, or similar.
- Any physiological parameter of wound exudates can be assessed using embodiments of the present invention. Particular parameters of interest may include, flow of wound exudates, volume rate, pH, temperature, hemoglobin concentration, color and tone.
- In one embodiment, the exudates system may evaluate exudates flow rates by measuring the rate at which a collection chamber fills, as seen for example in
FIGS. 19 and 25 . In one embodiment the exudates system may comprise a combination of a load cell with a measurement chamber to measure flow rate and an accelerometer to monitor orientation of the measurement chamber with respect to the vertical axis, as seen inFIG. 19 . Combined signals from the sensors may be used to determine the correct flow rate of exudates from the wound site independent of the orientation of the exudates system. - In yet another embodiment, the exudates system may have a chamber or
trap 98, as seen inFIG. 19 , into whichfluids 97 may pool, or flow so as to assist with obtaining more precise measurements regarding the physical state of the exudates. Measurements, such as flow rate may be taken of the pooled fluid, the flowing fluid, or both bysensors 101. This embodiment may be particularly useful for measuring the thermal mass of the exudate. - The exudates system may also comprise a
compartment 98 to be filled by exudates leaving the wound site as seen inFIG. 19 . In this embodiment, thecompartment 98 may be suitable for isolating exudates for analysis or to periodically weigh exudates removed from the wound site so as to assess the rate of fluid removed from the wound site over time. The compartment may include an automatic means for emptying when the fluid volume reaches a set level. Alternatively, the compartment may have an active system such asvalves 99, to empty thecompartment 98 when the fluid 97 reaches a set level. Fluid may enter thecompartment 98 through aninflow tube 96, and exit thecompartment 98, via anexit tube 103. - In this embodiment, the exudates system may comprise one or
more valves 99 to direct and/or interrupt flow through the wound drain. In yet another embodiment, the exudates system may draw off fluid for a sample without fully interrupting flow through the fluid line. The separated fluid as indicated inFIG. 19 , is analyzed within the line and allowed to remix further downstream. An alternative design may include a sampling port for taking a sample for analysis. - Table 1 depicts various flow rates and their potential clinical indications. By quantifying these flow rates, and assessing them together with the other physiological parameters discussed herein, an accurate prediction of wound health may be obtained.
-
TABLE 1 Exudate Volume Wound State Clinical Relevance Nothing dry wound desiccation Scant moist wound tissue (good) Normal Somewhat wet wound tissue Potential maceration Moderate saturated wound tissues Likely maceration Copious wound tissues are bathed in fluid maceration - In one example of the present technology, a collection canister was built to demonstrate flow measurement using the concept illustrated by the embodiment in
FIG. 25 .FIG. 25 is an alternative embodiment of the present invention depicting a wound exudate system and strain gauges disposed within an ancillary collection chamber. Such measurements may be taken by one or more sensors, including but not limited to straingauges 236, acapacitive level gauge 244,optical gauge elements 242, andelectrical gauge elements 240. Standard types of gauges for measuring weight or level are well known in the art. For example a strain gauge is based on a simple electrical circuit, wherein mechanical stress caused by change in weight causes the electrical resistance of the elements to change in proportion to the weight applied. A capacitance gauge reads a different level of capacitance between two points. In the present technology, the level offluid 237 in the chamber (e.g., the wound fluid) may have a different value of capacitance to that of air so the level of the fluid in the container may be determined. Alternatively, an optical gauge may use light to determine the distance between two points (e.g., the top of the canister and the fluid may indicate changes in the level of thefluid 237. - The system in this particular example may include a
small reservoir 230 in fluid communication with alarger reservoir 232, aninlet port 234 feeding into thesmall reservoir 230. Thesmall reservoir 230 was attached to thelarger reservoir 232 with aflexible support 238. A strain gauge basedload cell 236 was applied to the flexible support in order to measure flexure of the support duringuse 238. Saline was used to approximate the fluid under measurement during the study. The system was also equipped withelectrical gauge elements 240,optical gauge elements 242, acapacitive level gauge 244. Therefore, the example demonstrates that individually, or if necessary in combination, different sensor types may be used to determine flow rate. - In this example, small amounts of fluid were fed through the inlet and the sensor response was recorded on a computer (PC). During injection of fluid, the reservoir was subjected to chaotic disturbances in an attempt to disrupt the sensor readings. Such inputs would be typical of movements experienced by the device during a mobile use scenario. The response data was filtered using finite impulse response and infinite impulse response filters. The filters were used to remove movement artifacts and recover a usable signal from the input.
- In general, the signal detected the system was related to the weight of the small reservoir. This is in turn related to the time integral of the flow rate of fluid into the container. Thus the flow rate was able to be extracted from the reservoir weight signal.
- A
valve 246 was used between the small reservoir and the large reservoir in order to drain and reset the reservoir when it became too full. The flow dynamics of this emptying process can be used to determine viscosity related information about the fluid under study. -
FIG. 26 depicts aprocess 260 that is further related to flow measurement ofFIG. 19 andFIG. 25 . Theprocess 260 includes (1) taking a flow reading in block S251; (2) removing any movement artifacts in block S252 (1); and (3) calculating a flow rate in block S253 based on methods known in the art and, in particular, those disclosed herein. If the calculated flow rate is acceptable, measurements will continue to be taken. If the flow rate is not acceptable an alarm or alert is triggered in block S254. The flow rates calculated inprocess 260 can also be mapped in a graph as seenFIG. 27 . As withprocess 260, the spectral maps described here in various values along the flow rate map may indicate an onset of infection and/or bleeding, i.e., 262. - Exudate flow rate, which may be measured by the methods described herein, or any of the methods known to those of ordinary skill in the art is a reliable predictor of wound health. In certain embodiments of the present invention, flow rate values, and changes in flow rate values may be detected through various means and may also be useful in determining how to most optimally change from one therapy to another. In one instance, a relative change from a highly exudating wound to one of a superficially exudating wound may be useful to monitor. A transition from a highly exudating wound to a superficially exudating wound may provide useful information as to when a patient can be transferred from a more expensive to a less expensive therapy. An example of an expensive therapy is NPWT, while an example of a lower cost therapy is moist wound dressings or bandages. In one instance, changes in the rate of exudates flowing from the wound site may be indicative of a change in the wound state. In another instance, changes in the composition of the wound exudates may indicate a clinically relevant change in the wound state.
- In another embodiment, color assessment of a disposable element within the device, or disposable electrodes within tube maybe possible. It may also be possible to map color profiles of exudates to pH. Several fluorescent nanoparticles systems can change color based on pH. In addition, a conjugated polymer could be used to do the same (redox potentials will change based on the pH of the local environment).
- Additionally, it is possible to have a color changing element in contact with the exudates that is responsive to local pH changes and a reusable reader element that can analyze the pH changes via monitoring color response of the color changing element.
- Temperature is useful for assessing bleeding events as well as to monitor for infection. Core blood is generally warmer than the interstitial fluids in the dermis. In general, embodiments using a disposable metallic element for measuring temperature values, as well as embodiments with reusable probes are envisaged.
- In one aspect of the present invention, near infrared spectroscopy/visible spectroscopy may be used to detect the values of oxygen in hemoglobin present in wound exudates. The presence of oxygen may indicate the presence of hemoglobin, and therefore blood. In aspects of the present invention this could trigger an indicator, or cause one of the pinch mechanisms described herein to clamp a wound drain line to prevent further bleeding. In yet other embodiments, this event would provide a caregiver with appropriate treatment guidelines.
- Tone and/or luminocity may be used to describe the color of the exudates. Changes in tone and/or luminocity may be indicative of changes in the physiological state of a wound and its stage of healing. A quantification system for evaluating the wideband absorption spectrum may also be useful for assessing the color and tone of the exudate.
- In one embodiment, a wound system may include one or more laser diodes that provide very narrow wavelengths used to perform measurements. In this case a spectral map and/or vector can be generated by using a single detector in combination with multiple laser diodes and/or one or more scanning laser diodes. A scanning laser diode can produce a modulated wavelength through modulation of the driving signals produced by the drive electronics. Such modulation makes for simplified removal of artifacts caused by ambient light interference, movement and the like.
- A method for quantitative, real time spectral detection and assessment may be a steady, pulsed or modulated near infrared spectroscopy or functional near infrared spectroscopy technique. It may use multiple wavelength spectroscopy and the like. In one case, a exudates system may include a color analysis system in combination with a white light source. A color analysis system may comprise one or more photodiodes in combination with one or more bandpass filters in order to provide separate responses for segments of the light spectrum. One or more outputs from each band are generated, with each output providing the spectral component of a vector. Output vectors can be mapped to exudates states, thereby creating vector maps useful for determining the state of the exudates and thus, statements about the physiological condition of the wound, as seen in
FIGS. 22-24 . -
FIG. 20 is one example of an absorption map or tone map for analyzing different absorption wavelengths. As depicted inFIG. 20 , by representative example only, a two-dimensional map shows absorption of asource spectrum 108 along a blue 104, yellow 105, red 106, andNIR 107 wavelength. This particular example depicts broadband detection for the colors indicated. However, alternative embodiments, a single broadband detector could also be used. Particular values seen in an absorption map can be translated into a particular assessment of a wound state. By way of example only, a process performed by the processor may be encoded to signal an alarm or pinch a drain line if a particular tonal color reaches a certain level. -
FIG. 21 depicts a flow diagram of various operations performed to assess the color or tonal characteristics of a wound exudate. An initial block S110 may obtain various spectral components. Next, any ambient light may be removed in block S112 to increase the accuracy of any spectral readings from the wound exudate. Once block S112 is completed, tone vectors are calculated in block S114 from the readings obtained from block S110. Tone vectors may be calculated by any means known in the art. However, in preferred embodiments, the vectors may be calculated using the following equation: -
-
Equation 1 is a linear weighting equation that casts portions of the sensor spectrum (each portion indicated by a coordinate Xi) into an nth order vector space. Each portion of the spectrum is weighted by a scalar weighting parameter Ai (in this example only, more generally the weighting parameters may be equations, or algorithms that better map responses into the vector space, adjust for subject parameters, as well as adjust for changes in ambient conditions). - The relationship computed in the equation may be used to map readings from individual sensors, wavelengths, and/or spectral bands into the nth dimensional figures, as disclosed herein. This process may be done to essentially create a map of the input responses into a quantifiable space such that diagnostic information may be more readily extracted from the collection of input signals. So for example, delta maps into this Nth order space, regions of which may have statistically significant relationships to various disease states, contraindications for the existing therapy, etc. By correlating where patient data falls on the map, and examining the historical data and trending data, the technology can assist in decision making with regards to therapeutic decisions.
- These tone vectors are then compared to a tone map block S116 containing standard or acceptable tonal values. In assessing for any potential problems block S118, the tone vectors from block S114 are compared to the accepted values in block S116. If any of those values fall short of or exceed the acceptable ranges from block S116, a predetermined action in block S120 is performed. A programmed action may include, triggering an audible alarm from actuating one of the latch mechanisms described herein.
- In particular, luminocity and tone may be indicative of infection, bleeding or increased edema in a wound, all conditions requiring urgent attention. Certain embodiments of the present invention may compare and analyze detected tone and luminocity values with predetermined values of tone and luminocity to provide a patient or caregiver with valuable treatment guidelines (see
FIGS. 22, 23, and 24 ). Values of these various parameters may be combined into vector maps. -
FIG. 22 is a two-dimensional vector map 200 based on a range of colors at a givenluminocity 201, measured from the wound exudate.Map 200 represents data points along thespectral graph 206, as shown inFIG. 23 . Different locations on thevector map 200 may indicate the likelihood or actual occurrence of various events related to wound state. For example at location 202 a normal exudate trend may be indicated, whilelocations Location 205 may indicate the presence of an actual bleeding event.Graph 206 inFIG. 23 represents a line graph of three individual spectral profiles over a given period of time. -
FIG. 24 is a three-dimensional vector map, similar to the two-dimensional map shown inFIG. 22 , which is based on a range of colors measured from the wound exudate. Spectral components of wound exudate translated into vectors, may be mapped in such a two or three-dimensional map. By increasing the number of color channels, and therefore the number of wavelengths able to be detected, the sensitivity and accuracy of the system can be improved. Various points along the vector map, whether two or three-dimensional, may also indicate a trend of wound health. Forexample curve 220 may indicate an initial trend whilecurve 222 may indicate a slight progression towards infection.Curve 224 may indicate the actual onset of infection whilecurve 226 may indicate various regions with a probability of infection. - Given points, (e.g., 227 and 228) in the vector map may indicate a certain wound state. Such a wound state may correspond to a prescribed treatment guideline. These treatment guidelines may include, but are not limited to varying the settings of an NPWT, or closing off a wound drain. Presence of bacteria or other infection may necessitate administration of antibiotics to the patient.
- Qualitative analysis of the color spectrum of wound exudates may be another valuable tool for assessing wound health. Table 2 depicts various exudates, their color, transparency and possible clinical indications.
-
TABLE 2 Type of Exudate Color, Transparency Viscosity Indications Serous-transudate clear, straw colored, low viscosity, watery normal (good) Fibrinous cloudy low viscosity, strands contains fibrin Sero-sanguinous clear, pink low viscosity watery normal (good) Sanguinous red low viscosity and blood vessel trauma watery Sero-purulent murky yellow to high viscosity infection creamy coffee Purulent yellow, grey, green high viscosity presence of inflammatory cells, infection, pyogenic organisms Hemo-purulent Dark, red, high viscosity established infection, and sticky presence of neutrophils, bacteria, inflammatory cells with blood leakage due to vessel damage Hemorrhagic Red thick infection with trauma - Practically, when considering diagnostic and treatment options for a patient suffering from a wound, in general, a clinician does not want to be inundated with data. It is desirable that an exudate assessment system analyze values detected from a wound, and provide decision support for the user regarding treatment options, rather than just data presentation. To that end, the system of the present invention is capable of analyzing the values of the data obtained from the sensors and/or detectors. Once an analysis is conducted the system may provide an assessment of the wound, as well as treatment guidelines.
- Embodiments of methods and apparatuses according to the present invention may detect values of various parameters in real time, and perform analyzing processes as shown in
FIGS. 28 and 29 . These analyzing processes provide not only real time detection, which gives a much more accurate and reliable assessment of the wound, but also gives real time treatment suggestions, as they evaluate the current state of a wound, and not exudate that has been sitting in a collection canister for an extended period of time. - The exudates system may comprise processing components to perform various processes that provide or output a wound state condition or treatment option, which may include, among other things, microelectronic circuits such as discrete circuits, microcontrollers, microprocessors, ASICs, FPGAs or the like, to condition and analyze sensor data to meaningfully interpret the physiological parameters of the exudates. The processing components may be located integrally within the system so that the sensors, light sources and processing components are all contained within the same device. In an alternative embodiment, the processing components may be remotely located from the other parts of the system.
- The process performed for analysis are generally adaptive and may be based on, one or more of the following: an averaged one-dependence estimators (AODE), Kalman filters, Markov models, back propagation artificial neural networks, Baysian networks, basis functions, support vector machines, k-nearest neighbors algorithms, case-based reasoning, decision trees, Gaussian process regression, information fuzzy networks, regression analysis, self-organizing maps, logistic regression, time series models such as autoregression models, moving average models, autoregressive integrated moving average models, classification and regression trees, multivariate adaptive regression splines. The sensor data may be analyzed from multiple sources using sensor fusion approaches. The specific process may be evolved using supervised learning, unsupervised learning, and/or reinforcement learning approaches. In addition, the device may comprise associated power sources and the like to drive the onboard electronics (sensors, microelectronic circuits, communication elements).
- When tone and luminocity values are analyzed in combination with temperature readings, flow rate and NIR readings, a comprehensive statement may be made about the actual state of the exudates. By applying the processes described above to the various physiological parameters, including tone, luminocity, temperature and flow, a clinically appropriate set of treatment guidelines may be delivered by the system, thus eliminating the need for the caregiver or patient to have to interpret large amounts of data and make a subjective determination.
-
FIG. 28 is a flow diagram of an exemplary process to obtain and analyze parameter readings, as well as present and display warnings and treatment options. - The process of
FIG. 28 is also referred to as a read and assess loop. The wound monitoring system may be at a sleep state to reserve or reduce power consumption. The system may be “woken up” during a wake-up phase S201, in response to some input. This input may be any type of stimuli such as motion, or as a result of a timer. Once awake, the system will obtain parameter readings S203. After block S203, the device may immediately return to a rest state in block S222. If this is the logic path followed by the device, the readings obtained in block S203 may also be stored in a memory. - If after obtaining readings in block S203, the system does not immediately return to rest S222, the device may be conditioned and cleaned in block S205. In the first mode from wake up, the device may be in a loop where it simply wakes up takes a reading, potentially stores it and then rests, as already described. If instead of resetting, the device needs to switch modes to monitoring disturbances from block 207 it will need to activate a conditioning function, which may be there to obtain the raw signals from 207 and prepare them for analysis (e.g., converting from analog to digital signals depending on sensor type or other forms of data conversion/signal conditioning know in the art). It may also be necessary to clean the signals because many signals can have “noise” or spurious data which may need to be filtered out before processing in 209.
- If after obtaining readings in block S203, the system does not immediately return to rest S222, the device may be conditioned and cleaned in block S205. This cleaning step aids in obtaining an accurate reading and filtering out any extraneous data or artifacts. After blocks S205 the readings obtained in block S203 are converted to vectors and assigned a corresponding weight S209. The weighting of the various readings can be based on any factor known in the art. By way of representative example only, one parameter such as temperature may be given a higher weight than pH, or vice versa. Such weighting can be changed from patient to patient or as applied to the same patient. Such weighting may also be assigned based on historical weights of various parameters. Once the readings are vectorized and weighted, the processor in block S213 compares the vectorized and weighted values to a vector map. At this point, the processor analyzes the data, and makes a determination, based on the vector's location on a vector map, as to whether the value is in a safe region in block S217. What constitutes a safe region is also a parameter that may be predetermined and stored in a memory associated with the processor. If, it is determined in block S217A the readings are in a safe region but appear to be trending toward an unsafe region, the weights of those readings may be adjusted in block S217(b) to assign a higher priority to said values. Next, based on the adjusted weights, the system makes a determination as to whether or not it is worth warning a user S217(c) of the trend toward an unsafe region. If based on predetermined values, the processor determines that it is in fact worth warning a user, then a warning is issued in block S217(d). If not, the system returns to the rest state in block S222 for power minimizing consumption.
- If the vectorized and weighted reading is not in a safe region, the processor determines whether or not the unsafe reading is a new occurrence in block S219. If it is a new occurrence, the alert weight of the occurrence is increased in block S220. Once the alert weight is increased, the processor returns to the rest state S222. If the device or processor determines that the unsafe reading is not a new occurrence, a determination is made as to whether the alert weight is critical in block S219(b).
- If the alert weight is not critical, then the alert weight is merely increased in block S220 and the device returns to rest state S222. If the alert weight is critical, the processor determines in block S219(c) which region of the vector map the value falls in and what type of condition is therefore indicated by the value of the readings. Based on the region and type of event detected at in block S219(c), an action is initiated in block S219(d). An action may be an alert, an alarm, a pinching of a wound drain, or any other type of event or warning, which aids the user in assessing or treating the wound. If the action taken at block S219(d) is resolved, as determined in block S219(e) the device and/or processor will record the event in block S219(f) and return to rest S222. If the event has not been resolved, the action at block S219(d) will be repeated or sustained.
- At block S203 at the read and assess loop, readings are obtained.
FIG. 29 is a detailed logic diagram of operations performed in block S203. Once the processor or device “wakes up,” thesensors 301 are then powered up. Once the sensors are powered up, parameter values may be obtained S303. As depicted inFIG. 29 , parameters such as spectral content of the wound exudate S303(a), flow S303(b), temperature S303(c), biomarker detection S303(d), and viscosity (e) are detected and measured. While these parameters are illustrated inFIG. 29 , they are by way of representative example only and the current invention can be used to measure any parameter present in wound exudate. These values are then converted to digital signals in block S305, which may be done as a low power conversion to reduce power requirements. Once the values have been digitized, the processor in block S309 performs a check for values that may be statistical outliers. - At block S309, as part of the outlier analysis, the values may be stored in a memory to be incorporated into the historical data S309(a). If the sample is determined to be a good sample in block S311, the processor will perform a specific calibration S313 to adjust to the specific present conditions. Once this adjustment is performed, the processor in block S315 may perform the conditioning and cleaning similarly as in step S207. If the sample is determined by the processor in blocks to not be a good sample, the event is recorded in block S311(a). If the bad sample is a recurring problem, which may be detected by prior historical values, an error message is displayed to the user in block 311(c). If the problem sample is not recurring, the processor returns to rest S311(d).
- After the processor has determined the wound state and/or treatment information, that data may be provided or communicated to a user or patient. As discussed above, the system is capable of communicating or providing values and treatment guidelines to a user. In addition, the system is also capable of communication directly with a negative pressure wound therapy device in order to effectuate necessary changes.
- The system comprises means for alerting a patient or caregiver to the presence of an abnormal state, quantity, or condition of the exudates. In this case, it may comprise one or more lights, a display, a speaker, a vibrating element, or similar in order to communicate information to a patient or caregiver.
- The device may further include wireless communication capabilities so as to deliver relevant information about the wound exudates to the NPWT device. Such information may include the presence of blood in the exudates, the presence of bacteria, a change in the absorption spectrum of the exudates, a change in the flow rate of the exudates, and the like.
- Results of the wound assessment may be displayed through any type of graphical user interface, monitor or other type of display. Results of wound assessment may also be conveyed to a clinician and/or patient by the use of indicators as seen. Indicators may be any visual indicators such as lights, or audible indicators such as buzzers or alarms, or a haptic communication device such as a vibration motor to alert the clinician or patient when a particular event has been detected.
- The exudates system may comprise a means for communicating via a network such a cellular network, a wireless personal area network (WPAN), wide area network (WAN), metropolitan area network (MAN), local area network (LAN), campus area network (CAN), virtual private network (VPN), internet, intranet or near-me area network (NAN).
- The exudates system may be arranged as a node in a network, thus providing an element in a ring, mesh star, fully connected, line, tree or bus network topology. In one embodiment the exudates system communicates relevant values and as a node in a mesh or star network topology.
- The exudates system may comprise means for interfacing with a local telecommunications network, such as a cellular network via a locally positioned mobile handset, a wireless node, a wireless modem, phone adaptor or the like.
- The exudates system may communicate relevant information through the network using various protocols such as IrDA, Bluetooth, UWB, Z-WAVE, ANT, or ZigBee. Preferably, the relevant information is sent via low power protocols such as Blue tooth low energy, ANT or ZigBee.
- The exudates system may comprise an integrated power switch such that power is automatically provided to the onboard microcircuitry as soon as the system, or a wound device with which the system is associated, is positioned so as to effectively assess exudates. In another embodiment, the system may comprise a proximity sensor to awaken the system itself or wound device from sleep. The sleep function may be useful to reserve power during periods of nonuse.
- In another embodiment, the system may include a wound dressing with fluorescent biomarkers as shown in
FIG. 7 .Biomarkers 50 may be employed for detecting various conditions.Biomarkers 50 can be assessed by externally positionedoptical sensors 52, thus providing a non-contact way to assess exudates properties. Theoptical sensors 52 can use colorimetric analyses to read thebiomarkers 50 and detect the presence, absence or quantity of a particular value of a physiological parameter. In one embodiment, an optionallight source 56 may be used to emit light into the wound exudate. - In this particular embodiment,
optical sensors 52 may be located on the outer surface of an opaque, or opticallytransparent tube 54. Biomarkers can change based on local pH, local impedance, local redox potentials, color, and can fluoresce based on certain criteria, all of which are known in the art. As they interact with the exudates they are useful to detect the presence or absence of certain biological materials. The exudates system may read, detect or assess the biomarkers through optical means (color change, fluorescence, etc.), or electrical means (pH, redox, impedance, etc.). - In yet another embodiment, the system may detect presence of an infection, including but not limited to methicillin resistant staphylococcus aureus (MRSA) or vancomycin resistant enterococci (VRE), to alert a patient at home that they need in-patient hospital treatment. These various infections may be detected by assessing biomarkers integrated within the system, or by assessing the value of other physiological parameters, including but not limited to temperature.
- In one preferred embodiment, each process performed by the system can be done in a non-contact fashion such that the sensors and electronics supporting the sensors do not come into contact with the exudates. This allows the components of the system to be reused, as cross contamination is avoided, thus sparing the expense of having to use replaceable sensors with each use.
- Non-contact is defined herein as not having direct contact between the fluid under analysis, and the sensory elements. Thin membranes in the drainage lines can be used to sense pressure, temperature, etc. (see
FIG. 17 ).FIG. 18 depicts an alternative embodiment of a wound exudate system, which contains pressure sensors. In the present embodiment, the wound exudate system may contain two sections adjacent to awound drain 89. Those two regions are indicated inFIG. 17 as 91 and 92 at the interface of the system and the drain where the wall thickness of the system is reduced. At the precise interface between the system and the wound drain, a thin membrane is disposed thereon (not shown). The thinner membrane allows pressure sensors to detect a pressure inside the drain atlocations location 91 a and a second pressure P2 is obtained for the pressure reading atlocation 92 a. The difference between these two pressure readings can be used to establish, for example, flow rate, viscosity. The configuration described above may be self-contained within a disposable shunt for placement over an existing wound drain line, or designed as an integral component of a wound drain line. -
FIG. 18 depicts an embodiment similar to that as seen inFIG. 17 . However, the embodiment depicted inFIG. 18 measures thermal mass vis-à-vis a microheating element disposed in each ofrecesses - The exudates system may comprise a means for pinching off, or otherwise closing a wound drainage line in the event of an anomaly (such as the presence of blood in the exudates). In this case, the device may comprise an actuator that may be deployed so as to squeeze the line during an adverse event. In another case, the actuator may be arranged such that it is forcefully retracted during normal operation and is released during an adverse event, thus clamping down onto a wound drain line and pinching off fluid flow.
-
FIGS. 9-16 depict various control mechanisms for controlling or stopping the flow of any fluid from a wound. These control mechanisms may include pinch lines to control the flow of exudates upon detection of a certain physiological value. These pinch mechanisms may also be referred to herein as latches. Different types of latches may be activated by different mechanisms. In one mechanism, the latch is an active material element that will change shape in response to a stimulus. Suitable active materials include shape memory alloys, electroactive polymers, piezoceramics, etc. In this particular embodiment, the active material latch is designed such that it releases upon stimulation. - If used as part of an NPWT system in response to a certain parameter value, the system may pinch the wound drainage line so as to force a fault (blocked line fault) on the NPWT device. In this case, the system need not have its own means for alerting the patient or caregiver of an adverse event, but rather may trigger an alarm that is present in existing NPWT devices to achieve this goal.
- In another embodiment, a suitable latch is designed with an integrated
resistive heating element 80, areed 81 and a disbondable fastenedregion 83, as seen inFIG. 15 . The reed is deformed during manufacturing and bonded with the disbondable fastenedregion 83 in the deformed state. The reed is also bonded to anattachment point 84, in which the bond is not broken. The latch system is designed such that fluid can flow through an adjacent channel when the reed is held to the disbondable region, but that fluid flow through the channel onfluid line 85 may be blocked when the reed is released 87. Upon heating of theheating element 80, the disbondable fastenedregion 83 melts, deforms, or vaporizes, causing the deformed reed to break away from the fastenedregion 83. During this process, the reed bridges thefluid line 85, as shown inFIG. 16 , preventing flow and optionally triggering a blockage alarm. Other alternative latch designs will be evident to someone skilled in the art. - The wound drain may have a particular shape so as to maintain laminar flow of the exudate during suction, in addition to providing for an actuating means for pinching off a wound drain line in the event of an adverse event such as bleeding. Representative examples of this embodiment can be seen in
FIGS. 9 and 10 . The mechanical elements present in this embodiment are comprised of a solenoid basedpinch valve 65. As with traditional solenoid based apparatuses, thepinched valve 65 of the present embodiment contains acoil magnet 66 and acoiled actuator magnet 67. In the present embodiment, the pinched valve may be actuated to close or substantially narrow the interior wall of thewound drain 69. - This change of the channel width of the wound drain assists in detecting laminar to turbulent flow and may restrict flow for better analysis or measurement. The embodiment depicted in
FIG. 9 may be combined with any of the other embodiments described herein, such as aflow disruption element 70 as shown inFIG. 10 . When flow disruption element is present, analysis and detection may take place along ananalysis flow region 64 bysources 62 anddetectors 63. - As seen in
FIG. 11 , more than onesolenoid 71 actuator can be used to enhance the pinching affect.FIG. 12 depicts an alternative embodiment wherein multiple pinchingactuators 73 are disposed on opposite sides of a wound drain line. Theactuators 73, depicted inFIG. 12 can be activated in response to a stimulus, such as the presence of blood. In the event theactuators 73 are activated and pinch the drain line to prevent further bleeding. Analarm 74 can signal a blocked flow line. -
FIG. 13 depicts yet another embodiment of the present invention containing a spring loaded, resettable latch. Upon actuation, the spring loaded latch releases and causes the mechanism to pinch thewound drain line 79 in the event of the detection of some unwanted occurrence, such as bleeding, as shown inFIG. 14 . The spring loadedelement 75 once actuated can be reset and thelatch 77 may be re-secured, as shown inFIG. 13 . In this particular embodiment, electronics and power sources necessary for operation may be contained on an external housing. - In the case of a conventional dressing or bandage, the dressing component may be modified so as to easily integrate with the exudate assessment system. To enable this integration, the dressing may have electrical traces as an interface. The electrical traces may be printed using electroconductive inks (Ag, AgCl, C, Ni, etc.), or formed via several available RFID techniques known in the art, and embedded for electrically interacting with the exudate assessment system.
- Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
Claims (20)
1. A system for assessing wound exudate from a wound of a patient, the system comprising:
a wound treatment device for application to the wound;
a wound drain line for passage of wound exudate from the wound;
at least one sensor for measurement of one or more physiological parameters of wound exudate passed through the wound drain line; and
a controller coupled to the at least one sensor to receive sensor input therefrom, wherein the controller includes memory having instructions stored therein and a processor coupled to the memory, and wherein the instructions are executable by the processor to cause the processor to assess the one or more physiological parameters of the wound exudate based on the sensor input and provide a treatment guideline based on the assessment.
2. The system of claim 1 , further comprising a biomarker detectable by the at least one sensor to measure the one or more physiological parameters of wound exudate passed through the wound drain line, wherein:
the wound drain line includes an interior surface that at least partially defines an internal channel sized for the passage of wound exudate and an exterior surface disposed exteriorly of the internal channel;
the biomarker is located within the internal channel; and
the at least one sensor is located on the exterior surface such that the at least one sensor does not contact, and is not in fluid communication with, wound exudate passed through the internal channel.
3. The system of claim 2 , further comprising a light source to emit light into wound exudate passed through the internal channel to cause fluorescence of the biomarker, wherein:
the light source is located on the exterior surface;
the at least one sensor includes an optical sensor configured to detect fluorescence of the biomarker; and
the wound drain line includes an optically transparent tube.
4. The system of claim 1 , wherein:
the wound drain line includes an interior surface that at least partially defines an internal channel sized for the passage of wound exudate and an exterior surface disposed exteriorly of the internal channel;
a wall extending between the interior surface and the exterior surface has a first thickness in locations where the at least one sensor is absent; and
the wall has a second thickness less than the first thickness in locations where the at least one sensor is present.
5. The system of claim 4 , wherein:
the at least one sensor includes two pressure sensors spaced from one another and located outside of the internal channel such that the two pressure sensors do not contact, and are not in fluid communication with, wound exudate passed through the internal channel; and
two thin membranes are disposed on the wall in locations corresponding to the two pressure sensors.
6. The system of claim 4 , wherein:
the at least one sensor includes two thermal mass sensors spaced from one another and located outside of the internal channel such that the two thermal mass sensors do not contact, and are not in fluid communication with, wound exudate passed through the internal channel; and
two thin membranes are disposed on the wall in locations corresponding to the two thermal mass sensors.
7. The system of claim 1 , further comprising a compartment fluidly coupled to the wound drain line and configured to collect wound exudate passed through the wound drain line, wherein:
the at least one sensor is arranged in close proximity to the compartment;
the at least one sensor includes a strain gauge, a capacitive level gauge, or an optical gauge; and
the instructions are executable by the processor to cause the processor to calculate a flow rate of wound exudate based on the sensor input.
8. The system of claim 1 , further comprising:
a first reservoir fluidly coupled to the wound drain line to receive wound exudate passed therethrough; and
a second reservoir in fluid communication with the first reservoir and attached to the first reservoir by a flexible support,
wherein the at least one sensor includes a load cell coupled to the flexible support and configured to measure flexure of the support in use of the system.
9. The system of claim 8 , wherein:
the at least one sensor includes a sensing device provided separately from the load cell;
the sensing device includes a capacitive level gauge or an optical gauge; and
the instructions are executable by the processor to cause the processor to calculate a flow rate of wound exudate based on sensor input provided by the sensing device.
10. The system of claim 9 , wherein the instructions are executable by the processor to cause the processor to remove any movement artifacts from the sensor input, to determine if the calculated flow rate is acceptable, and to trigger an alert or alarm in response to a determination that the calculated flow rate is not acceptable.
11. The system of claim 1 , wherein the instructions are executable by the processor to cause the processor to:
obtain readings based on the sensor input when the processor and the at least one sensor are powered up;
condition and clean the sensor input to filter out extraneous data or artifacts;
assign one or more weights to the conditioned and cleaned sensor input;
compare the weighted sensor input to a vector map;
determine whether the weighted sensor input is in a safe region on the vector map; and
selectively storing the weighted sensor input in the memory in response to a determination that the weighted sensor input is in the safe region on the vector map.
12. The system of claim 11 , wherein to obtain readings based on the sensor input, the instructions are executable by the processor to cause the processor to:
measure spectral content of the wound exudate;
measure flow of the wound exudate;
measure temperature of the wound exudate;
detect a biomarker of the system; or
measure viscosity of the wound exudate.
13. A system for assessing wound exudate from a wound of a patient, the system comprising:
a wound treatment device for application to the wound;
a wound drain line for passage of wound exudate from the wound;
at least one sensor for measurement of one or more physiological parameters of wound exudate passed through the wound drain line, wherein the at least one sensor is not disposed in fluid communication with wound exudate passed through the wound drain line; and
a controller coupled to the at least one sensor to receive sensor input therefrom, wherein the controller includes memory having instructions stored therein and a processor coupled to the memory, and wherein the instructions are executable by the processor to cause the processor to assess the one or more physiological parameters of the wound exudate based on the sensor input and provide a treatment guideline based on the assessment.
14. The system of claim 13 , further comprising a biomarker detectable by the at least one sensor to measure the one or more physiological parameters of wound exudate passed through the wound drain line, wherein:
the wound drain line includes an interior surface that at least partially defines an internal channel sized for the passage of wound exudate and an exterior surface disposed exteriorly of the internal channel;
the biomarker is located within the internal channel; and
the at least one sensor is located on the exterior surface.
15. The system of claim 13 , wherein:
the wound drain line includes an interior surface that at least partially defines an internal channel sized for the passage of wound exudate and an exterior surface disposed exteriorly of the internal channel;
a wall extending between the interior surface and the exterior surface has a first thickness in locations where the at least one sensor is absent; and
the wall has a second thickness less than the first thickness in locations where the at least one sensor is present.
16. The system of claim 15 , wherein:
the at least one sensor includes two pressure sensors or two thermal mass sensors spaced from one another and located outside of the internal channel; and
two thin membranes are disposed on the wall in locations corresponding to the two pressure sensors or the two thermal mass sensors.
17. The system of claim 13 , further comprising a compartment fluidly coupled to the wound drain line and configured to collect wound exudate passed through the wound drain line, wherein:
the at least one sensor is arranged in close proximity to the compartment;
the at least one sensor includes a strain gauge, a capacitive level gauge, or an optical gauge; and
the instructions are executable by the processor to cause the processor to calculate a flow rate of wound exudate based on the sensor input.
18. The system of claim 17 , wherein the instructions are executable by the processor to cause the processor to remove any movement artifacts from the sensor input, to determine if the calculated flow rate is acceptable, and to trigger an alert or alarm in response to a determination that the calculated flow rate is not acceptable.
19. The system of claim 13 , wherein the instructions are executable by the processor to cause the processor to:
obtain readings based on the sensor input when the processor and the at least one sensor are powered up;
condition and clean the sensor input to filter out extraneous data or artifacts;
assign one or more weights to the conditioned and cleaned sensor input;
compare the weighted sensor input to a vector map;
determine whether the weighted sensor input is in a safe region on the vector map; and
selectively storing the weighted sensor input in the memory in response to a determination that the weighted sensor input is in the safe region on the vector map.
20. The system of claim 19 , wherein to obtain readings based on the sensor input, the instructions are executable by the processor to cause the processor to:
measure spectral content of the wound exudate;
measure flow of the wound exudate;
measure temperature of the wound exudate;
detect a biomarker of the system; or
measure viscosity of the wound exudate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/398,552 US20210369937A1 (en) | 2010-12-08 | 2021-08-10 | Integrated system for assessing wound exudates |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42100310P | 2010-12-08 | 2010-12-08 | |
PCT/US2011/063781 WO2012078781A1 (en) | 2010-12-08 | 2011-12-07 | Integrated system for assessing wound exudates |
US201313992637A | 2013-07-26 | 2013-07-26 | |
US16/237,421 US11116884B2 (en) | 2010-12-08 | 2018-12-31 | Integrated system for assessing wound exudates |
US17/398,552 US20210369937A1 (en) | 2010-12-08 | 2021-08-10 | Integrated system for assessing wound exudates |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/237,421 Continuation US11116884B2 (en) | 2010-12-08 | 2018-12-31 | Integrated system for assessing wound exudates |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210369937A1 true US20210369937A1 (en) | 2021-12-02 |
Family
ID=46207499
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/992,637 Active 2032-05-21 US10207031B2 (en) | 2010-12-08 | 2011-12-07 | Integrated system for assessing wound exudates |
US16/237,421 Active 2032-08-07 US11116884B2 (en) | 2010-12-08 | 2018-12-31 | Integrated system for assessing wound exudates |
US17/398,552 Abandoned US20210369937A1 (en) | 2010-12-08 | 2021-08-10 | Integrated system for assessing wound exudates |
US17/399,271 Abandoned US20210369938A1 (en) | 2010-12-08 | 2021-08-11 | Integrated system for assessing wound exudates |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/992,637 Active 2032-05-21 US10207031B2 (en) | 2010-12-08 | 2011-12-07 | Integrated system for assessing wound exudates |
US16/237,421 Active 2032-08-07 US11116884B2 (en) | 2010-12-08 | 2018-12-31 | Integrated system for assessing wound exudates |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/399,271 Abandoned US20210369938A1 (en) | 2010-12-08 | 2021-08-11 | Integrated system for assessing wound exudates |
Country Status (6)
Country | Link |
---|---|
US (4) | US10207031B2 (en) |
EP (1) | EP2648793B1 (en) |
JP (2) | JP5965409B2 (en) |
CN (1) | CN103347561B (en) |
CA (1) | CA2819475C (en) |
WO (1) | WO2012078781A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200281519A1 (en) * | 2017-09-10 | 2020-09-10 | Smith & Nephew Plc | Systems and methods for inspection of encapsulation and components in sensor equipped wound dressings |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2340085T5 (en) | 2006-09-28 | 2014-04-16 | Smith & Nephew, Inc. | Portable wound therapy system |
US10226610B2 (en) | 2007-10-26 | 2019-03-12 | Electrochemical Oxygen Concepts, Inc. | Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability |
US10912869B2 (en) | 2008-05-21 | 2021-02-09 | Smith & Nephew, Inc. | Wound therapy system with related methods therefor |
US8177763B2 (en) | 2008-09-05 | 2012-05-15 | Tyco Healthcare Group Lp | Canister membrane for wound therapy system |
JP2014500538A (en) | 2010-10-12 | 2014-01-09 | タニス,ケヴィン ジェイ. | Medical equipment |
WO2012078781A1 (en) | 2010-12-08 | 2012-06-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
CN103347562B (en) | 2010-12-08 | 2016-08-10 | 康沃特克科技公司 | Wound exudate system accessory |
US9114054B2 (en) * | 2011-07-24 | 2015-08-25 | Oakwell Distribution, Inc. | System for monitoring the use of medical devices |
CN202236824U (en) * | 2011-08-29 | 2012-05-30 | 惠州市华阳医疗电子有限公司 | Negative-pressure wound treatment system with extravasate flow rate alarming function |
JP6382185B2 (en) | 2012-05-22 | 2018-08-29 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | Apparatus and method for wound treatment |
EP2968706B1 (en) * | 2013-03-14 | 2022-12-07 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
US9737649B2 (en) | 2013-03-14 | 2017-08-22 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
USD764654S1 (en) | 2014-03-13 | 2016-08-23 | Smith & Nephew, Inc. | Canister for collecting wound exudate |
AU2014306876B2 (en) | 2013-08-13 | 2019-05-02 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
CA3161435A1 (en) * | 2014-02-07 | 2015-08-13 | Willow Innovations, Inc. | Methods, apparatus, and system for expression of human breast milk |
USD764048S1 (en) | 2014-05-28 | 2016-08-16 | Smith & Nephew, Inc. | Device for applying negative pressure to a wound |
USD764653S1 (en) | 2014-05-28 | 2016-08-23 | Smith & Nephew, Inc. | Canister for collecting wound exudate |
USD764047S1 (en) | 2014-05-28 | 2016-08-16 | Smith & Nephew, Inc. | Therapy unit assembly |
USD765830S1 (en) | 2014-06-02 | 2016-09-06 | Smith & Nephew, Inc. | Therapy unit assembly |
USD770173S1 (en) | 2014-06-02 | 2016-11-01 | Smith & Nephew, Inc. | Bag |
WO2015195720A1 (en) * | 2014-06-16 | 2015-12-23 | The Regents Of The University Of California | Methods and apparatus for monitoring wound healing using impedance spectroscopy |
CA2956572C (en) | 2014-07-31 | 2023-06-27 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
CN104189991A (en) * | 2014-09-11 | 2014-12-10 | 昆山韦睿医疗科技有限公司 | Color discrimination method and device for wound exudates and negative-pressure treatment system |
WO2016081400A1 (en) * | 2014-11-21 | 2016-05-26 | Elwha Llc | Systems to monitor body portions for injury after impact |
JP6813489B2 (en) | 2014-12-30 | 2021-01-13 | スミス アンド ネフュー インコーポレイテッド | Systems and methods for performing decompression therapy |
AU2015374632B2 (en) | 2014-12-30 | 2020-09-10 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
KR101633497B1 (en) * | 2015-02-10 | 2016-06-24 | (주)시지바이오 | A method and apparatus for measuring volum of wound |
EP3328458B1 (en) | 2015-07-29 | 2020-05-06 | Innovative Therapies Inc. | Wound therapy device pressure monitoring and control system |
CN108292529A (en) | 2015-10-07 | 2018-07-17 | 史密夫和内修有限公司 | System and method for application decompression treatment |
CN105232229B (en) * | 2015-10-19 | 2018-07-24 | 中国人民解放军第四军医大学 | A kind of intelligent radio sensing dressing that can monitor wound healing in real time |
JP7055103B2 (en) * | 2015-12-07 | 2022-04-15 | エレクトロケミカル オキシジェン コンセプツ インコーポレーテッド | Devices and methods for controlling tissue oxygenation for wound healing and tissue viability promotion |
EP3187205B1 (en) * | 2015-12-30 | 2021-01-27 | Paul Hartmann AG | Methods and devices for performing a negative pressure wound therapy |
JP2019508124A (en) * | 2016-02-12 | 2019-03-28 | スミス アンド ネフュー インコーポレイテッド | System and method for detecting operating conditions of decompression therapy |
DE102017204776B4 (en) * | 2016-03-23 | 2021-09-23 | Stihler Electronic Gmbh | Modular blood warmer and procedure |
WO2017195038A1 (en) | 2016-05-13 | 2017-11-16 | Smith & Nephew Plc | Sensor enabled wound monitoring and therapy apparatus |
AU2017261814B2 (en) * | 2016-05-13 | 2022-05-19 | Smith & Nephew, Inc. | Automatic wound coupling detection in negative pressure wound therapy systems |
US11452808B2 (en) * | 2016-07-08 | 2022-09-27 | Convatec Technologies Inc. | Fluid flow sensing |
US11369730B2 (en) | 2016-09-29 | 2022-06-28 | Smith & Nephew, Inc. | Construction and protection of components in negative pressure wound therapy systems |
USD835648S1 (en) | 2016-10-27 | 2018-12-11 | Smith & Nephew, Inc. | Display screen or portion thereof with a graphical user interface for a therapy device |
AU2018230992B2 (en) | 2017-03-07 | 2023-07-27 | Smith & Nephew, Inc. | Reduced pressure therapy systems and methods including an antenna |
WO2018162732A1 (en) | 2017-03-09 | 2018-09-13 | Smith & Nephew Plc | Apparatus and method for imaging blood in a target region of tissue |
WO2018162736A1 (en) | 2017-03-09 | 2018-09-13 | Smith & Nephew Plc | Wound dressing, patch member and method of sensing one or more wound parameters |
EP3609449A1 (en) | 2017-04-11 | 2020-02-19 | Smith & Nephew PLC | Component positioning and stress relief for sensor enabled wound dressings |
WO2018195101A1 (en) | 2017-04-19 | 2018-10-25 | Smith & Nephew, Inc. | Negative pressure wound therapy canisters |
AU2018269113A1 (en) | 2017-05-15 | 2019-11-21 | Smith & Nephew Plc | Negative pressure wound therapy system using eulerian video magnification |
EP3635732A1 (en) | 2017-05-15 | 2020-04-15 | Smith & Nephew plc | Wound analysis device and method |
EP3406274B1 (en) * | 2017-05-23 | 2023-01-18 | Sofradim Production | A surgical drain |
EP3406273B1 (en) * | 2017-05-23 | 2022-03-30 | Sofradim Production | A surgical drain |
CN110753512A (en) | 2017-06-23 | 2020-02-04 | 史密夫及内修公开有限公司 | Sensor positioning for performing sensor wound monitoring or treatment |
US11712508B2 (en) | 2017-07-10 | 2023-08-01 | Smith & Nephew, Inc. | Systems and methods for directly interacting with communications module of wound therapy apparatus |
GB201804502D0 (en) | 2018-03-21 | 2018-05-02 | Smith & Nephew | Biocompatible encapsulation and component stress relief for sensor enabled negative pressure wound therapy dressings |
RU175660U1 (en) * | 2017-07-25 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Device for recording the appearance of exudate in a postoperative wound |
GB201809007D0 (en) | 2018-06-01 | 2018-07-18 | Smith & Nephew | Restriction of sensor-monitored region for sensor-enabled wound dressings |
SG11202000913XA (en) | 2017-08-10 | 2020-02-27 | Smith & Nephew | Positioning of sensors for sensor enabled wound monitoring or therapy |
GB201804971D0 (en) | 2018-03-28 | 2018-05-09 | Smith & Nephew | Electrostatic discharge protection for sensors in wound therapy |
GB201718870D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew Inc | Sensor enabled wound therapy dressings and systems |
GB201718859D0 (en) * | 2017-11-15 | 2017-12-27 | Smith & Nephew | Sensor positioning for sensor enabled wound therapy dressings and systems |
EP3687380A1 (en) | 2017-09-27 | 2020-08-05 | Smith & Nephew plc | Ph sensing for sensor enabled negative pressure wound monitoring and therapy apparatuses |
WO2019072531A1 (en) | 2017-09-28 | 2019-04-18 | Smith & Nephew Plc | Neurostimulation and monitoring using sensor enabled wound monitoring and therapy apparatus |
JP6959104B2 (en) * | 2017-11-02 | 2021-11-02 | 日東電工株式会社 | Drainage drainage management system |
BR112020006513A2 (en) * | 2017-11-08 | 2020-09-29 | Mölnlycke Health Care Ab | biosensor and dressing system for associated injury |
EP3706619B1 (en) | 2017-11-09 | 2024-04-24 | ConvaTec Technologies Inc. | Ostomy monitoring system |
US11559438B2 (en) | 2017-11-15 | 2023-01-24 | Smith & Nephew Plc | Integrated sensor enabled wound monitoring and/or therapy dressings and systems |
CA3090284A1 (en) | 2018-02-06 | 2019-08-15 | Adlore, Inc. | Devices, methods, and systems for the treatment and/or monitoring of damaged tissue |
EP4331481A3 (en) * | 2018-03-29 | 2024-04-03 | 3M Innovative Properties Co. | Wound therapy system with wound volume estimation |
EP3806789B1 (en) * | 2018-06-15 | 2023-10-25 | Coloplast A/S | Accessory device of a wound dressing system, and related methods for communicating operating state |
EP3823684A1 (en) * | 2018-07-16 | 2021-05-26 | KCI Licensing, Inc. | Fluid instillation apparatus for use with negative-pressure system incorporating wireless therapy monitoring |
GB2592508B (en) | 2018-09-12 | 2022-08-31 | Smith & Nephew | Device, apparatus and method of determining skin perfusion pressure |
USD893514S1 (en) | 2018-11-08 | 2020-08-18 | 11 Health And Technologies Limited | Display screen or portion thereof with graphical user interface |
GB201820388D0 (en) * | 2018-12-14 | 2019-01-30 | Smith & Nephew | Changing therapy devices or wound dressings in reduced pressure wound therapy |
GB201820668D0 (en) | 2018-12-19 | 2019-01-30 | Smith & Nephew Inc | Systems and methods for delivering prescribed wound therapy |
GB201820927D0 (en) | 2018-12-21 | 2019-02-06 | Smith & Nephew | Wound therapy systems and methods with supercapacitors |
GB2614490B (en) | 2019-03-18 | 2023-12-06 | Smith & Nephew | Design rules for sensor integrated substrates |
US11318241B2 (en) * | 2019-03-27 | 2022-05-03 | Medsix Inc. | System and method for wound monitoring |
EP4021360A4 (en) | 2019-08-28 | 2023-09-13 | Adlore, Inc. | Apparatuses, systems, and methods for the treatment of damaged tissue |
GB201914443D0 (en) | 2019-10-07 | 2019-11-20 | Smith & Nephew | Sensor enabled negative pressure wound monitoring apparatus with different impedances inks |
CN112546313B (en) * | 2020-12-10 | 2022-09-02 | 广州润虹医药科技股份有限公司 | Negative pressure treatment system |
CN114904145A (en) * | 2021-02-09 | 2022-08-16 | 明基材料股份有限公司 | Wound treatment system |
TWI759106B (en) * | 2021-02-09 | 2022-03-21 | 明基材料股份有限公司 | Wound treatment system |
DE102021126851A1 (en) | 2021-10-15 | 2023-04-20 | Elixion Medical GmbH | Device and method for flow determination |
DE102021212234A1 (en) | 2021-10-29 | 2023-05-04 | New Ventures GmbH | Sensor assembly for an organ transport system |
GB202301329D0 (en) * | 2023-01-31 | 2023-03-15 | Smith & Nephew | Negative pressure wound therapy devices and methods utilizing a turbine |
Family Cites Families (624)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7198046B1 (en) * | 1991-11-14 | 2007-04-03 | Wake Forest University Health Sciences | Wound treatment employing reduced pressure |
US6511454B1 (en) * | 1998-05-29 | 2003-01-28 | Nidek Co., Ltd. | Irrigation/aspiration apparatus and irrigation/aspiration cassette therefore |
ATE337765T1 (en) | 1999-04-02 | 2006-09-15 | Kinetic Concepts Inc | VACUUM-ASSISTED CLOSURE DEVICE WITH HEATING AND COOLING DEVICE |
US7947033B2 (en) * | 1999-04-06 | 2011-05-24 | Kci Licensing Inc. | Systems and methods for detection of wound fluid blood and application of phototherapy in conjunction with reduced pressure wound treatment system |
US7799004B2 (en) | 2001-03-05 | 2010-09-21 | Kci Licensing, Inc. | Negative pressure wound treatment apparatus and infection identification system and method |
KR20030009325A (en) | 1999-11-29 | 2003-01-29 | 힐-롬 서비시즈, 인크. | Wound treatment apparatus |
GB0011202D0 (en) | 2000-05-09 | 2000-06-28 | Kci Licensing Inc | Abdominal wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
US8111165B2 (en) | 2002-10-02 | 2012-02-07 | Orthocare Innovations Llc | Active on-patient sensor, method and system |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
EP1593956A4 (en) | 2002-11-01 | 2007-09-19 | Hamamatsu Photonics Kk | Disease diagnosing method, method for creating data for disease diagnosis, and device for creating data for disease diagnosis |
CN1771061B (en) | 2003-01-09 | 2010-05-12 | 聚合物器官股份有限公司 | Biomedical foams |
JP3770241B2 (en) | 2003-03-04 | 2006-04-26 | 株式会社日立製作所 | Personal authentication device and personal authentication method |
CN102743785A (en) | 2003-08-14 | 2012-10-24 | 美利肯公司 | Silver-containing wound care device, composition therefor, and method of producing |
GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
US8157792B2 (en) | 2004-02-26 | 2012-04-17 | Haemonetics Corporation | Wound drainage suction relief |
JP2005293241A (en) | 2004-03-31 | 2005-10-20 | Yamaguchi Univ | Automatic diagnostic expert system |
US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US10413644B2 (en) | 2004-04-27 | 2019-09-17 | Smith & Nephew Plc | Wound treatment apparatus and method |
GB0409446D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
CA2619925A1 (en) | 2005-09-07 | 2007-03-15 | Tyco Healthcare Group Lp | Wound dressing with vacuum reservoir |
EP2898908A1 (en) | 2005-09-07 | 2015-07-29 | Smith & Nephew, Inc. | Self contained wound dressing apparatus |
DK2010245T3 (en) * | 2005-11-21 | 2016-01-18 | Joshua David Smith | WOUND CARE SYSTEM |
RU2428209C2 (en) | 2006-01-23 | 2011-09-10 | КейСиАй ЛАЙСЕНЗИНГ, ИНК. | Wound treatment system and method with using ultrasonic surgical purification |
CN101378796B (en) | 2006-02-06 | 2011-09-28 | 凯希特许有限公司 | Systems and methods for improved connection to wound dressings in conjunction with reduced pressure wound treatment systems |
US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
GB2439928A (en) | 2006-07-13 | 2008-01-16 | Ethicon Inc | Hydrogel wound dressings exhibiting reduced fiber losses |
US20100030132A1 (en) | 2006-09-28 | 2010-02-04 | Jeffrey Niezgoda | Apparatus and method for wound, cavity, and bone treatment |
US8116852B2 (en) | 2006-09-29 | 2012-02-14 | Nellcor Puritan Bennett Llc | System and method for detection of skin wounds and compartment syndromes |
ES2447296T3 (en) | 2006-10-13 | 2014-03-11 | Bluesky Medical Group Incorporated | Pressure control of a medical vacuum pump |
CN110251740A (en) | 2006-10-13 | 2019-09-20 | 凯希特许有限公司 | For providing the reduced pressure delivery system for the treatment of to lower severity wound |
JP2010510837A (en) | 2006-11-30 | 2010-04-08 | メデラ ホールディング アーゲー | Wound treatment device |
US8152751B2 (en) | 2007-02-09 | 2012-04-10 | Baxter International Inc. | Acoustic access disconnection systems and methods |
US8057411B2 (en) * | 2007-04-25 | 2011-11-15 | General Patent, Llc | Wound care vacuum bandaging in combination with acoustic shock wave applications |
US20080269582A1 (en) | 2007-04-28 | 2008-10-30 | Hebah Noshy Mansour | Methods and devices for surgical drains with sensors |
FR2916356B1 (en) | 2007-05-25 | 2009-08-28 | Urgo Soc Par Actions Simplifie | NOVEL AGENT FOR RELOCATING ACTIVE INGREDIENTS IN DRESSINGS CONTAINING AT LEAST ONE FATTY BODY |
GB0712737D0 (en) | 2007-07-02 | 2007-08-08 | Smith & Nephew | Apparatus |
WO2009020612A1 (en) | 2007-08-06 | 2009-02-12 | Stb Lifesaving Technologies, Inc. | Methods and dressing for sealing internal injuries |
GB2452720A (en) | 2007-09-11 | 2009-03-18 | Ethicon Inc | Wound dressing with an antimicrobial absorbent layer and an apertured cover sheet |
EP2190500B8 (en) | 2007-09-17 | 2016-08-10 | vTitan Corporation Private Limited | High precision infusion pumps |
US20110021922A1 (en) * | 2007-10-03 | 2011-01-27 | Neorad As | Monitoring the flow of fluid |
EP2203137B1 (en) | 2007-10-11 | 2016-02-24 | Spiracur, Inc. | Closed incision negative pressure wound therapy device |
HUE041864T2 (en) | 2007-11-21 | 2019-06-28 | Smith & Nephew | Wound dressing |
ES2555204T3 (en) | 2007-11-21 | 2015-12-29 | T.J. Smith & Nephew Limited | Suction and bandage device |
US20100266794A1 (en) | 2007-12-12 | 2010-10-21 | Wright Robin E | Hydrophilic gel materials and methods of making |
US20090177051A1 (en) * | 2008-01-09 | 2009-07-09 | Heal-Ex, Llc | Systems and methods for providing sub-dressing wound analysis and therapy |
US8152785B2 (en) | 2008-03-13 | 2012-04-10 | Tyco Healthcare Group Lp | Vacuum port for vacuum wound therapy |
US20090234306A1 (en) | 2008-03-13 | 2009-09-17 | Tyco Healthcare Group Lp | Vacuum wound therapy wound dressing with variable performance zones |
GB0805162D0 (en) | 2008-03-19 | 2008-04-23 | Bristol Myers Squibb Co | Antibacterial wound dressing |
CN102046121A (en) | 2008-04-04 | 2011-05-04 | 3M创新有限公司 | Wound dressing with micropump |
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
CN102083478B (en) | 2008-05-21 | 2014-05-21 | 莫利斯·托帕斯 | Wound healing device |
ITAR20080022A1 (en) | 2008-05-26 | 2009-11-27 | Daniele Guidi | DRAINAGE DEVICE, IN PARTICULAR FOR ASPIRATION IN CASE OF SUCTION THERAPIES, FISTULAS, SURGICAL WOUND DEFICIENCIES, DECUBITUS INJURIES, TRAUMAS AND SIMILAR INJURIES. |
CN103536975B (en) | 2008-05-30 | 2016-10-05 | 凯希特许有限公司 | At the reduced-pressure, compression systems and device used in part that bend the body |
CN102046117B (en) | 2008-05-30 | 2014-05-07 | 凯希特许有限公司 | Reduced-pressure, linear wound closing bolsters and systems |
US20200113741A1 (en) | 2008-05-30 | 2020-04-16 | Kci Licensing, Inc. | Dressing with tissue viewing capability |
US20100022990A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Technologies, L.P. | Pump system for negative pressure wound therapy and improvements thereon |
US8460698B2 (en) | 2008-08-01 | 2013-06-11 | Milliken & Company | Composite article suitable for use as a wound dressing |
US20100036334A1 (en) | 2008-08-08 | 2010-02-11 | Tyco Healthcare Group Lp | Wound Dressing of Continuous Fibers |
GB2463523B (en) | 2008-09-17 | 2013-05-01 | Medtrade Products Ltd | Wound care device |
GB0904582D0 (en) | 2008-09-24 | 2009-04-29 | Lumina Adhesives | Switchable adhesives |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
WO2010038231A1 (en) | 2008-10-02 | 2010-04-08 | L.R.R.& D. Ltd. | Interface layer wound dressing |
WO2010053870A1 (en) | 2008-11-07 | 2010-05-14 | Kci Licensing, Inc. | Reduced-pressure, wound-treatment dressings and systems |
EP2868300B1 (en) | 2008-11-14 | 2018-06-06 | KCI Licensing, Inc. | Fluid pouch, system, and method for storing fluid from a tissue site |
EP2355762B1 (en) | 2008-11-18 | 2019-09-25 | KCI Licensing, Inc. | Reduced-pressure, composite manifolds |
EP3159034B1 (en) | 2008-11-25 | 2020-01-08 | KCI Licensing, Inc. | Device for delivery of reduced pressure to body surfaces |
WO2010080907A1 (en) | 2009-01-07 | 2010-07-15 | Spiracur Inc. | Reduced pressure therapy of the sacral region |
US8162907B2 (en) | 2009-01-20 | 2012-04-24 | Tyco Healthcare Group Lp | Method and apparatus for bridging from a dressing in negative pressure wound therapy |
GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
US9395473B2 (en) * | 2009-03-20 | 2016-07-19 | Nanolambda, Inc. | Nano-optic filter array based sensor |
US20190298578A1 (en) | 2009-03-26 | 2019-10-03 | Stephen Shulman | Vented emergency wound dressings with anti-thrombogenic layers |
US10792404B2 (en) | 2009-04-10 | 2020-10-06 | Kci Licensing, Inc. | Methods and devices for applying closed incision negative pressure wound therapy |
GB2470040A (en) | 2009-05-06 | 2010-11-10 | Systagenix Wound Man Ip Co Bv | Wound dressing material comprising N-acetyl cysteine |
KR101699992B1 (en) | 2009-06-16 | 2017-01-26 | 백스터 인터내셔널 인코포레이티드 | Hemostatic sponge |
CN104095709B (en) | 2009-06-16 | 2017-06-13 | 3M创新有限公司 | Conformable Medical with self-supporting substrate |
US20100324516A1 (en) | 2009-06-18 | 2010-12-23 | Tyco Healthcare Group Lp | Apparatus for Vacuum Bridging and/or Exudate Collection |
US8535282B2 (en) * | 2009-07-14 | 2013-09-17 | Southwest Research Institute | Wound healing sensor techniques |
US8469936B2 (en) | 2009-07-15 | 2013-06-25 | Kci Licensing, Inc. | Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers |
US20110066123A1 (en) | 2009-09-15 | 2011-03-17 | Aidan Marcus Tout | Medical dressings, systems, and methods employing sealants |
EP3398619B1 (en) | 2009-11-09 | 2020-03-25 | 3M Innovative Properties Company | Medical articles and methods of making using immiscible material |
EP2498988B1 (en) | 2009-11-09 | 2019-02-27 | 3M Innovative Properties Company | Medical articles and methods of making using miscible composition |
GB0919659D0 (en) | 2009-11-10 | 2009-12-23 | Convatec Technologies Inc | A component for a wound dressing |
CN105797224B (en) | 2009-12-22 | 2019-11-08 | 史密夫和内修有限公司 | Device and method for negative pressure wound therapy |
CA2786101C (en) | 2010-01-20 | 2018-08-07 | Kci Licensing, Inc. | Foam wound inserts with regions of higher and lower densities, wound dressings, and methods |
US8791315B2 (en) | 2010-02-26 | 2014-07-29 | Smith & Nephew, Inc. | Systems and methods for using negative pressure wound therapy to manage open abdominal wounds |
US10709883B2 (en) | 2010-03-04 | 2020-07-14 | Donald Spector | Bandage with microneedles for antimicrobial delivery and fluid absorption from a wound |
US8721606B2 (en) | 2010-03-11 | 2014-05-13 | Kci Licensing, Inc. | Dressings, systems, and methods for treating a tissue site |
US8469935B2 (en) | 2010-03-11 | 2013-06-25 | Kci Licensing, Inc. | Abdominal treatment systems, delivery devices, and methods |
US8430867B2 (en) | 2010-03-12 | 2013-04-30 | Kci Licensing, Inc. | Reduced-pressure dressing connection pads, systems, and methods |
US8814842B2 (en) | 2010-03-16 | 2014-08-26 | Kci Licensing, Inc. | Delivery-and-fluid-storage bridges for use with reduced-pressure systems |
US9358158B2 (en) | 2010-03-16 | 2016-06-07 | Kci Licensing, Inc. | Patterned neo-epithelialization dressings, systems, and methods |
DK2552371T3 (en) | 2010-03-31 | 2020-09-14 | Pharmaplast Sae | Wound care dressing, a method and a production line for producing the wound care dressing |
US8632512B2 (en) | 2010-04-09 | 2014-01-21 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
CA2796334A1 (en) | 2010-04-13 | 2011-10-20 | Kci Licensing, Inc. | Compositions with reactive ingredients, and wound dressings, apparatuses, and methods |
US8604265B2 (en) | 2010-04-16 | 2013-12-10 | Kci Licensing, Inc. | Dressings and methods for treating a tissue site on a patient |
US20190381222A9 (en) | 2010-04-16 | 2019-12-19 | Kci Licensing, Inc. | Reduced-Pressure Sources, Systems, And Methods Employing A Polymeric, Porous, Hydrophobic Material |
GB201006986D0 (en) | 2010-04-27 | 2010-06-09 | Smith & Nephew | Wound dressing |
GB201008347D0 (en) | 2010-05-19 | 2010-07-07 | Smith & Nephew | Wound protection |
USRE48117E1 (en) | 2010-05-07 | 2020-07-28 | Smith & Nephew, Inc. | Apparatuses and methods for negative pressure wound therapy |
US10639404B2 (en) | 2010-06-03 | 2020-05-05 | Wound Healing Technologies, Llc | Wound dressing |
ES2831299T3 (en) | 2010-06-17 | 2021-06-08 | Covalon Tech Inc | Antimicrobial Silicone Based Wound Dressing |
US9265665B2 (en) | 2010-07-19 | 2016-02-23 | Kci Licensing, Inc. | Inflatable off-loading wound dressing assemblies, systems, and methods |
US8795246B2 (en) | 2010-08-10 | 2014-08-05 | Spiracur Inc. | Alarm system |
US9194792B2 (en) * | 2010-09-07 | 2015-11-24 | Fresenius Medical Care Holdings, Inc. | Blood chamber for an optical blood monitoring system |
GB201015656D0 (en) | 2010-09-20 | 2010-10-27 | Smith & Nephew | Pressure control apparatus |
BR112013012785A2 (en) | 2010-11-25 | 2020-10-20 | Bluestar Silicones France Sas | composition i - ii and products and uses thereof |
WO2012078781A1 (en) | 2010-12-08 | 2012-06-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
CN103347562B (en) | 2010-12-08 | 2016-08-10 | 康沃特克科技公司 | Wound exudate system accessory |
US8613733B2 (en) | 2010-12-15 | 2013-12-24 | Kci Licensing, Inc. | Foam dressing with integral porous film |
GB2488749A (en) | 2011-01-31 | 2012-09-12 | Systagenix Wound Man Ip Co Bv | Laminated silicone coated wound dressing |
US9226737B2 (en) | 2011-02-04 | 2016-01-05 | University Of Massachusetts | Negative pressure wound closure device |
US9107990B2 (en) | 2011-02-14 | 2015-08-18 | Kci Licensing, Inc. | Reduced-pressure dressings, systems, and methods for use with linear wounds |
CA2827124C (en) | 2011-04-12 | 2019-03-12 | Kci Licensing, Inc. | Evaporative fluid pouch and systems for use with body fluids |
GB201106491D0 (en) | 2011-04-15 | 2011-06-01 | Systagenix Wound Man Ip Co Bv | Patterened silicone coating |
CA2828634A1 (en) | 2011-04-29 | 2012-11-01 | Kci Licensing, Inc. | Aptamer -modified polymeric materials for the binding of therapeutic factors in a wound environment |
GB201108229D0 (en) | 2011-05-17 | 2011-06-29 | Smith & Nephew | Tissue healing |
JP6449015B2 (en) | 2011-05-26 | 2019-01-09 | ケーシーアイ ライセンシング インコーポレイテッド | System and method for stimulation and activation of liquids used in infusion therapy |
EP3159020B1 (en) | 2011-06-07 | 2019-11-06 | Smith & Nephew plc | Wound contacting members |
US9681993B2 (en) | 2011-06-07 | 2017-06-20 | Kci Licensing, Inc. | Solutions for bridging and pressure concentration reduction at wound sites |
JP6193855B2 (en) | 2011-07-26 | 2017-09-06 | ケーシーアイ ライセンシング インコーポレイテッド | System and method for treating a tissue site using reduced pressure, including a reduced pressure interface having a multi-lumen conduit for contacting the manifold |
JP6131253B2 (en) | 2011-07-26 | 2017-05-17 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | System and method for controlling operation of a reduced pressure treatment system |
GB201113515D0 (en) | 2011-08-04 | 2011-09-21 | Convatec Technologies Inc | A dressing |
DE102011081818A1 (en) | 2011-08-30 | 2013-02-28 | Beiersdorf Ag | Active skin coatings |
WO2013033131A1 (en) | 2011-08-30 | 2013-03-07 | Avery Dennison Corporation | Silicone absorbent adhesive layer |
EP2944298B1 (en) | 2011-08-31 | 2017-05-17 | KCI Licensing, Inc. | Inline storage pouches for use with body fluids |
DE202011108806U1 (en) | 2011-09-02 | 2012-09-03 | BLüCHER GMBH | Wound dressing with permeable layer |
ES2523377T5 (en) | 2011-09-09 | 2018-04-19 | Paul Hartmann Ag | Abdominal dressing with application help |
WO2013040080A1 (en) | 2011-09-12 | 2013-03-21 | Protege Biomedical, Llc | Composition and dressing for wound treatment |
DK2572737T3 (en) | 2011-09-26 | 2016-06-27 | Bsn Medical Gmbh | improved wound dressing |
US9393354B2 (en) | 2011-11-01 | 2016-07-19 | J&M Shuler Medical, Inc. | Mechanical wound therapy for sub-atmospheric wound care system |
WO2013064831A1 (en) | 2011-11-01 | 2013-05-10 | Brightwake Limited | Wound dressings, and yarn useful therein |
EP3669841B1 (en) | 2011-11-15 | 2024-05-15 | Solventum Intellectual Properties Company | Medical dressings, systems, and methods with thermally-enhanced vapor transmission |
US9132040B2 (en) | 2011-11-17 | 2015-09-15 | Ethicon, Inc. | Dressing device |
CA2855972C (en) | 2011-11-18 | 2019-08-27 | Kci Licensing, Inc. | Tissue treatment systems and methods having a porous substrate with a compressed region and an expanded region |
CA2854634A1 (en) | 2011-11-21 | 2013-05-30 | Kci Licensing, Inc. | Systems, devices, and methods for identifying portions of a wound filler left at a tissue site |
US10940047B2 (en) | 2011-12-16 | 2021-03-09 | Kci Licensing, Inc. | Sealing systems and methods employing a hybrid switchable drape |
EP3308809B1 (en) | 2012-01-10 | 2019-08-21 | KCI Licensing, Inc. | Systems for delivering fluid to a wound therapy dressing |
CA3081085C (en) | 2012-01-25 | 2022-03-22 | The University Of Akron | Fluorinated polymerizable hydrogels for wound dressings and methods of making same |
GB201201751D0 (en) | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
AU2013215067A1 (en) | 2012-02-02 | 2014-06-12 | Kci Licensing, Inc. | Foam structure wound inserts for directional granulation |
AU2012370527B2 (en) | 2012-02-21 | 2017-05-11 | Solventum Intellectual Properties Company | A multi-orientation canister for use with a reduced pressure treatment system |
EP3622971A1 (en) | 2012-02-29 | 2020-03-18 | Hollister Incorporated | Buffered adhesive compositions for skin-adhering medical products |
US10470936B2 (en) | 2012-02-29 | 2019-11-12 | Hollister Incorporated | Buffered adhesive compositions for skin-adhering medical products |
EP2636417B1 (en) | 2012-03-05 | 2017-04-26 | Lohmann & Rauscher GmbH | Wound treatment assembly and covering device for same |
US10046096B2 (en) | 2012-03-12 | 2018-08-14 | Smith & Nephew Plc | Reduced pressure apparatus and methods |
US10576037B2 (en) | 2012-03-14 | 2020-03-03 | MAM Holdings of West Florida, L.L.C. | Compositions comprising placental collagen for use in wound healing |
US9427505B2 (en) | 2012-05-15 | 2016-08-30 | Smith & Nephew Plc | Negative pressure wound therapy apparatus |
CN107280857A (en) | 2012-05-22 | 2017-10-24 | 史密夫及内修公开有限公司 | Wound healing device |
ES2769298T3 (en) | 2012-05-23 | 2020-06-25 | Smith & Nephew | Negative pressure wound therapy devices |
GB201209745D0 (en) | 2012-05-31 | 2012-07-18 | Convatec Technologies Inc | Wound dressing |
US10369259B2 (en) | 2012-06-03 | 2019-08-06 | Daniel Eduard Kleiner | Endoluminal vacuum therapy device |
CA2868854A1 (en) | 2012-06-28 | 2014-01-03 | Kci Licensing, Inc. | Wound connection pad with rfid and integrated strain gauge pressure sensor |
IN2015DN00399A (en) | 2012-07-16 | 2015-06-19 | Univ Massachusetts | |
WO2014012171A1 (en) | 2012-07-19 | 2014-01-23 | Innovotech, Inc. | Anti-microbial gel formulations containing a silver (i) periodate |
WO2014022400A1 (en) | 2012-07-30 | 2014-02-06 | Kci Licensing, Inc. | Reduced-pressure absorbent dressing, system for treating a tissue site, and method of manufacturing the dressing |
DK2879636T3 (en) | 2012-08-01 | 2017-06-19 | Smith & Nephew | Wound dressing |
WO2014028212A2 (en) | 2012-08-13 | 2014-02-20 | Kci Licensing, Inc. | Intelligent therapy system with evaporation management |
MX354749B (en) | 2012-08-28 | 2018-03-20 | 3M Innovative Properties Co | Chlorhexidine gluconate compositions, resin systems and articles. |
WO2014035245A1 (en) | 2012-08-31 | 2014-03-06 | Polyganics B.V. | Hemostatic foam |
WO2014039557A1 (en) | 2012-09-04 | 2014-03-13 | Integrated Healing Technologies | Wound dressing |
WO2014043238A2 (en) | 2012-09-12 | 2014-03-20 | Kci Licensing, Inc. | Systems and methods for collecting exudates in reduced-pressure therapy |
JP6534931B2 (en) | 2012-09-20 | 2019-06-26 | ローマン ウント ラウシェル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Negative pressure therapeutic device and film for manufacturing negative pressure therapeutic device |
GB201216928D0 (en) | 2012-09-21 | 2012-11-07 | I2R Medical Ltd | Portable medical device system |
US9877875B2 (en) | 2012-10-09 | 2018-01-30 | Parasol Medical LLC | Antimicrobial hydrogel formulation |
US9572968B2 (en) | 2012-10-11 | 2017-02-21 | Hanuman Pelican, Inc. | Compressive oxygen diffusive wound dressings |
JP6183831B2 (en) | 2012-10-23 | 2017-08-23 | 義之 小山 | Hydrogel forming material |
EP2912088B1 (en) | 2012-10-24 | 2019-09-18 | KCI Licensing, Inc. | Sulfhydryl-functionalized polymeric compositions for medical devices |
WO2014066674A1 (en) | 2012-10-24 | 2014-05-01 | Kci Licensing, Inc. | Amine-functionalized polymeric compositions for medical devices |
JP2016507663A (en) | 2012-12-20 | 2016-03-10 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | Processing of chemically modified cellulosic fibers |
BR112015014805A2 (en) | 2012-12-21 | 2017-07-11 | 3M Innovative Properties Co | medical bandage |
AU2013371545B2 (en) | 2013-01-03 | 2018-05-17 | 3M Innovative Properties Company | Moisture absorbing seal |
GB201309369D0 (en) | 2013-05-24 | 2013-07-10 | Smith & Nephew | Moisture indicating system |
WO2014113249A2 (en) | 2013-01-16 | 2014-07-24 | Kci Licensing, Inc. | Ion exchange enhanced absorbent systems |
US20140256925A1 (en) | 2013-03-05 | 2014-09-11 | The Penn State Research Foundation | Composite materials |
WO2014163733A2 (en) | 2013-03-13 | 2014-10-09 | Kci Licensing, Inc. | Expandable fluid collection canister |
WO2014158529A1 (en) | 2013-03-14 | 2014-10-02 | Kci Licensing, Inc. | A fluid collection canister with integrated moisture trap |
JP6259510B2 (en) | 2013-03-14 | 2018-01-10 | ケーシーアイ ライセンシング インコーポレイテッド | Multi-porous conduit |
WO2014158526A1 (en) | 2013-03-14 | 2014-10-02 | Kci Licensing, Inc. | Negative pressure therapy with dynamic profile capability |
US10492956B2 (en) | 2013-03-15 | 2019-12-03 | Kci Licensing, Inc. | Topical vacuum-press surgical incisional dressings, surgical adjuncts, hybrids and composites |
CA2902181A1 (en) | 2013-03-15 | 2014-09-25 | Smith & Nephew, Inc. | Dissolvable gel-forming film for delivery of active agents |
GB2549865B (en) | 2013-03-15 | 2018-01-17 | Aerpio Therapeutics Inc | Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases |
CA2907220A1 (en) | 2013-03-15 | 2014-10-16 | Euromed Inc. | Adhesive composition comprising silica |
EP2968648B1 (en) | 2013-03-15 | 2020-12-23 | Smith & Nephew plc | Wound dressing and method of treatment |
US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
EP2976095B1 (en) | 2013-03-15 | 2020-12-23 | 3M Innovative Properties Company | Wound healing compositions |
WO2014145271A1 (en) | 2013-03-15 | 2014-09-18 | Stb, Ltd. | Compositions having cylindrical volume, methods, and applicators for sealing injuries |
DK2983641T3 (en) | 2013-04-08 | 2020-03-16 | Univ Yeditepe | POLYMER-BASED HYDROGEL |
GB2512841B (en) | 2013-04-08 | 2020-07-15 | Brightwake Ltd | Absorbent wound dressings |
WO2014169250A1 (en) | 2013-04-11 | 2014-10-16 | President And Fellows Of Harvard College | Prefabricated alginate-drug bandages |
WO2014170461A1 (en) | 2013-04-17 | 2014-10-23 | Molnlycke Health Care Ab | Wound pad |
US10016380B2 (en) | 2013-05-01 | 2018-07-10 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US9884087B1 (en) | 2013-05-03 | 2018-02-06 | Chan Soon-Shiong Nanthealth Foundation | Compositions and methods of improved wound healing |
US10010658B2 (en) | 2013-05-10 | 2018-07-03 | Smith & Nephew Plc | Fluidic connector for irrigation and aspiration of wounds |
JP6424213B2 (en) | 2013-05-22 | 2018-11-14 | ザ ペン ステイト リサーチ ファウンデーション | Wound dressing and its application |
US10772767B2 (en) | 2013-06-28 | 2020-09-15 | 3M Innovative Properties Company | Fibrin-coated wound dressing |
US9993577B2 (en) | 2013-07-01 | 2018-06-12 | Trustees Of Boston University | Dissolvable hydrogel compositions for wound management and methods of use |
US10765774B2 (en) | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
BR112016002511A2 (en) | 2013-08-05 | 2017-08-01 | 3M Innovative Properties Co | support device |
AU2014307884B2 (en) | 2013-08-12 | 2019-03-28 | Bsn Medical Gmbh | Wound care article having a substantially polygonal or ellipsoid main surface and at least one recess arranged on one side |
WO2015022907A1 (en) | 2013-08-13 | 2015-02-19 | 生化学工業株式会社 | Drug containing cationized chitosan |
EP3038667B1 (en) | 2013-08-26 | 2019-10-09 | KCI Licensing, Inc. | Dressing interface with moisture controlling feature and sealing function |
GB2518199A (en) | 2013-09-13 | 2015-03-18 | Xiros Ltd | Method of producing a swellable polymer fibre |
US10342891B2 (en) | 2013-09-19 | 2019-07-09 | Medline Industries, Inc. | Wound dressing containing saccharide and collagen |
BR112016007156B1 (en) | 2013-10-02 | 2022-12-13 | 3M Innovative Properties Company | REDUCED PRESSURE SYSTEM |
CA2926370C (en) | 2013-10-10 | 2018-06-26 | F. Hoffmann-La Roche Ag | Carrier system for an object worn on the body and method of production |
SG11201603058UA (en) | 2013-10-18 | 2016-05-30 | Agency Science Tech & Res | Nanoparticle-containing hydrogels |
CA2926470C (en) | 2013-10-21 | 2023-03-14 | Smith & Nephew, Inc. | Negative pressure wound closure device |
GB201318842D0 (en) | 2013-10-24 | 2013-12-11 | First Water Ltd | Flexible hydrogel wound dressings |
US10946124B2 (en) | 2013-10-28 | 2021-03-16 | Kci Licensing, Inc. | Hybrid sealing tape |
EP3257486B1 (en) | 2013-10-30 | 2019-06-05 | KCI Licensing, Inc. | Condensate absorbing and dissipating system |
MX351120B (en) | 2013-11-07 | 2017-10-03 | Bsn Medical Gmbh | Medical dressing. |
GB2522178B (en) | 2013-11-12 | 2018-07-18 | First Water Ltd | Multilayer composition |
WO2015075406A1 (en) | 2013-11-19 | 2015-05-28 | Lipopeptide Ab | New treatment of chronic ulcers |
AU2014361828A1 (en) | 2013-12-12 | 2016-06-30 | Innovation Technologies, Inc. | Materials and methods for controlling infections |
JP6114481B2 (en) | 2013-12-31 | 2017-04-12 | スリーエム イノベイティブ プロパティズ カンパニー | Shape-compatible drape cover dressing |
WO2015112810A1 (en) | 2014-01-24 | 2015-07-30 | Avent, Inc. | Traumatic wound dressing system with conformal cover |
EP3939554A1 (en) | 2014-02-11 | 2022-01-19 | 3M Innovative Properties Company | Devices for applying closed incision negative pressure wound therapy |
DE102014202578A1 (en) | 2014-02-12 | 2015-08-13 | Aesculap Ag | Medical product and process for its preparation |
MX2016010532A (en) | 2014-02-14 | 2017-01-19 | Atomic Medical Innovations Inc | Systems and methods for tissue healing. |
US10610623B2 (en) | 2014-02-14 | 2020-04-07 | Kci Licensing, Inc. | Systems and methods for increasing absorbent capacity of a dressing |
EP3479803B1 (en) | 2014-02-28 | 2021-03-31 | 3M Innovative Properties Company | Hybrid drape having a gel-coated perforated mesh |
GB201404021D0 (en) | 2014-03-05 | 2014-04-23 | Lumina Adhesives Ab | Low cytotoxity switchable adhesive compositions, medical dressings and skin coverings, and methods of treatment using same |
US20150367019A1 (en) | 2014-03-12 | 2015-12-24 | Stb, Ltd. | Hemostatic compositions and methods |
AU2015231054B2 (en) | 2014-03-21 | 2019-11-07 | Medline Industries, Inc. | Wound management system and methods of using |
WO2015145457A1 (en) | 2014-03-24 | 2015-10-01 | Datt Mediproducts Limited | A ready to use biodegradable and biocompatible device and a method of preparation thereof |
GB2524510B (en) | 2014-03-25 | 2020-02-19 | Brightwake Ltd | Wound dressing impregnated with honey |
WO2015166197A1 (en) | 2014-04-30 | 2015-11-05 | Matoke Holdings Limited | Antimicrobial compositions |
WO2015168681A1 (en) | 2014-05-02 | 2015-11-05 | Kci Licensing, Inc. | Fluid storage devices, systems, and methods |
WO2015172108A1 (en) | 2014-05-09 | 2015-11-12 | Kci Licensing, Inc. | Dressing with contracting layer for linear tissue sites |
EP3791837B1 (en) | 2014-05-09 | 2024-07-17 | Solventum Intellectual Properties Company | Disruptive dressing for use with negative pressure and fluid instillation |
US10398610B2 (en) | 2014-05-13 | 2019-09-03 | The Procter & Gamble Company | Absorbent article with dual core |
GB2526267B (en) | 2014-05-14 | 2020-10-28 | Brightwake Ltd | Dressing for surgical drain |
CA2951043A1 (en) | 2014-06-05 | 2015-12-10 | Kci Licensing, Inc. | Dressing with fluid acquisition and distribution characteristics |
KR101743274B1 (en) | 2014-06-12 | 2017-06-02 | 주식회사 엘지화학 | Super absorbent polymer |
EP3666237B1 (en) | 2014-06-18 | 2023-11-01 | Smith & Nephew plc | Wound dressing |
CA2952604C (en) | 2014-06-18 | 2019-01-29 | Toray Industries, Inc. | Laminate and production method therefor |
WO2016006457A1 (en) | 2014-07-07 | 2016-01-14 | 株式会社村田製作所 | Negative-pressure closure therapy device |
MX2017000368A (en) | 2014-07-09 | 2017-05-12 | Lubrizol Advanced Mat Inc | Hydrogel compositions. |
JP2017523280A (en) | 2014-07-10 | 2017-08-17 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | Improvements in and relating to polymer materials |
EP3172265B1 (en) | 2014-07-24 | 2022-04-27 | ArthroCare Corporation | Resilient polysaccharide foams and uses thereof |
CA2956572C (en) | 2014-07-31 | 2023-06-27 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
US20170209615A1 (en) | 2014-08-04 | 2017-07-27 | Hospital Sant Joan De Deu | System for the immediate release of active agents |
US10583042B2 (en) | 2014-08-08 | 2020-03-10 | Neogenix, Llc | Wound care devices, apparatus, and treatment methods |
US9770369B2 (en) | 2014-08-08 | 2017-09-26 | Neogenix, Llc | Wound care devices, apparatus, and treatment methods |
EP3730159A1 (en) | 2014-08-11 | 2020-10-28 | KCI Licensing, Inc. | Protease modulating wound interface layer for use with negative pressure wound therapy |
WO2016040489A1 (en) | 2014-09-09 | 2016-03-17 | Shaoyi Jiang | Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methds for their use |
EP2995287A1 (en) | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Medical dressing |
EP2995324A1 (en) | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Medical dressing |
WO2016053829A1 (en) | 2014-10-01 | 2016-04-07 | 3M Innovative Properties Company | Porous devices, kits, and methods for debridement |
EP3434237B1 (en) | 2014-10-06 | 2021-11-17 | 3M Innovative Properties Company | Multi-function dressing structure for negative-pressure therapy |
RU2704259C2 (en) | 2014-10-06 | 2019-10-25 | Гатт Текнолоджиз Б. В. | Tissue-adhesive porous haemostatic product |
US9855364B2 (en) | 2014-10-15 | 2018-01-02 | Allison Coomber | Wound dressing materials incorporating anthocyanins derived from fruit or vegetable sources |
ES2636823T3 (en) | 2014-10-24 | 2017-10-09 | Sefar Ag | Wound coating material and manufacturing procedure |
US10485893B2 (en) | 2014-11-13 | 2019-11-26 | Sarasota Medical Products, Inc. | Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof |
EP3023083A1 (en) | 2014-11-20 | 2016-05-25 | Mölnlycke Health Care AB | Wound dressings |
WO2016086088A2 (en) | 2014-11-25 | 2016-06-02 | Northwestern University | Wound healing through sirt1 overexpression |
US20180303873A1 (en) | 2014-12-04 | 2018-10-25 | 3M Innovative Properties Company | Antimicrobial compositions comprising bioglass |
AU2015360637B2 (en) | 2014-12-09 | 2019-08-22 | Tangible Science, Inc. | Medical device coating with a biocompatible layer |
TW201622668A (en) | 2014-12-16 | 2016-07-01 | 準訊生醫股份有限公司 | Long-term effective patch structure |
US10398604B2 (en) | 2014-12-17 | 2019-09-03 | Kci Licensing, Inc. | Dressing with offloading capability |
CN107107598B (en) | 2014-12-18 | 2019-11-22 | 3M创新有限公司 | The method for handling bonded laminate patch |
CA2971621A1 (en) | 2014-12-19 | 2016-06-23 | 3M Innovative Properties Company | Adhesive article comprising a poly(meth)acrylate-based primer layer and methods of making same |
CN107249524A (en) | 2014-12-22 | 2017-10-13 | 史密夫及内修公开有限公司 | Negative pressure wound therapy device and method |
CA2972314A1 (en) | 2014-12-29 | 2016-07-07 | Smith & Nephew Plc | Negative pressure wound therapy apparatus and method of operating the apparatus |
JP6813489B2 (en) | 2014-12-30 | 2021-01-13 | スミス アンド ネフュー インコーポレイテッド | Systems and methods for performing decompression therapy |
JP6838812B2 (en) | 2014-12-30 | 2021-03-03 | スリーエム イノベイティブ プロパティズ カンパニー | Negative pressure wound dressing with absorbent adhesive sealant layer |
US10660851B2 (en) | 2015-01-02 | 2020-05-26 | Rxos Medical | Polyfunctional radical scavenger hydrogel formulation |
KR101949455B1 (en) | 2015-01-07 | 2019-02-18 | 주식회사 엘지화학 | Superabsorbent Polymers with Improved Anticaking Property And Method Of Preparing The Same |
GB201500430D0 (en) | 2015-01-12 | 2015-02-25 | Univ Birmingham | Dressing |
WO2016115448A1 (en) | 2015-01-15 | 2016-07-21 | Marshall University Research Corporation | Wound coverings comprising vitamin d and related methods |
GB201501330D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
GB201501333D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
GB201501334D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
US10500235B2 (en) | 2015-01-29 | 2019-12-10 | San Melix Laboratories, Inc. | Wound healing compositions comprising buckwheat honey and methylglyoxal and methods of use |
US20200093756A1 (en) | 2015-01-29 | 2020-03-26 | Sanmelix Laboratories, Inc. | Buckwheat honey and povidone-iodine wound-healing dressing |
KR101841469B1 (en) | 2015-01-30 | 2018-03-23 | (주)메디팁 | Method for manufacturing wound covering material using biopolymer and wound covering material using biopolymer manufactured by the same |
US10512707B2 (en) | 2015-02-02 | 2019-12-24 | University Of Southern California | System for sutureless closure of scleral perforations and other ocular tissue discontinuities |
EP3744359A1 (en) | 2015-02-02 | 2020-12-02 | 3M Innovative Properties Company | Customizable closed tissue site dressing for improved postoperative removal |
EP3253426B1 (en) | 2015-02-02 | 2019-11-20 | KCI Licensing, Inc. | Pressure-operated switch |
BR112017016545A2 (en) | 2015-02-03 | 2018-04-10 | Matoke Holdings Ltd | antimicrobial fibers and compositions |
GB201501965D0 (en) | 2015-02-05 | 2015-03-25 | Lumina Adhesives Ab | Polyurethane based switchable adhesives |
CA2979289C (en) | 2015-03-10 | 2022-10-18 | Covalon Technologies Inc. | Method for local reduction of microbial skin flora |
US10485892B2 (en) | 2015-03-10 | 2019-11-26 | Covalon Technologies Inc. | Method for local reduction of microbial skin flora |
US10478394B2 (en) | 2015-03-11 | 2019-11-19 | Wayne State University | Compositions and methods to promote wound healing |
GB201506236D0 (en) | 2015-04-13 | 2015-05-27 | Jellagen Pty Ltd | Modified collagen, methods of manufacture thereof |
EP3085344B1 (en) | 2015-04-21 | 2019-12-04 | Mölnlycke Health Care AB | A wound pad and a self-adhesive member comprising a wound pad |
AU2016294135A1 (en) | 2015-04-23 | 2017-11-09 | Sharklet Technologies, Inc. | Bilayered devices for enhanced healing |
DK3288508T3 (en) | 2015-04-27 | 2020-03-09 | Smith & Nephew | REDUCED PRESSURE DEVICES |
WO2016179575A1 (en) | 2015-05-07 | 2016-11-10 | Kci Liensing, Inc. | A controlled release iodine structure for use with wound care |
US10507259B2 (en) | 2015-05-08 | 2019-12-17 | First Quality Retail Services, Llc | Flexible absorbent pad |
WO2016182861A1 (en) | 2015-05-08 | 2016-11-17 | Kci Licensing, Inc. | Wound debridement by irrigation with ultrasonically activated microbubbles |
EP3294245B1 (en) | 2015-05-08 | 2019-09-04 | KCI Licensing, Inc. | Low acuity dressing with integral pump |
US20190298580A1 (en) | 2015-05-08 | 2019-10-03 | Kci Licensing, Inc. | Low-acuity dressing with integral pump |
EP3093031A1 (en) | 2015-05-11 | 2016-11-16 | 3M Innovative Properties Company | Wound care system |
EP3092987A1 (en) | 2015-05-11 | 2016-11-16 | 3M Innovative Properties Company | System for treatment of wounds using serum |
WO2016184918A1 (en) | 2015-05-18 | 2016-11-24 | Smith & Nephew Plc | Heat-assisted pumping systems for use in negative pressure wound therapy |
US10076594B2 (en) | 2015-05-18 | 2018-09-18 | Smith & Nephew Plc | Fluidic connector for negative pressure wound therapy |
US10501487B2 (en) | 2015-05-26 | 2019-12-10 | Monash University | Antibacterial bismuth complexes |
JP6185215B2 (en) | 2015-06-12 | 2017-08-23 | Jfeミネラル株式会社 | Skin wound or rough skin treatment |
US11559421B2 (en) | 2015-06-25 | 2023-01-24 | Hill-Rom Services, Inc. | Protective dressing with reusable phase-change material cooling insert |
CN113058083B (en) | 2015-06-29 | 2024-07-26 | 3M创新知识产权公司 | Device for negative pressure therapy and irrigation |
US10426938B2 (en) | 2015-07-14 | 2019-10-01 | Kci Licensing, Inc. | Medical dressing interface devices, systems, and methods |
EP3117806B1 (en) | 2015-07-16 | 2020-06-10 | Lohmann & Rauscher GmbH | Wound treatment assembly |
BR112018001561B1 (en) | 2015-07-24 | 2021-10-26 | Molnlycke Health Care Ab | ABSORBENT ANTIMICROBIAL WOUND DRESSING AND METHOD OF PREPARATION OF THE SAME |
US10583228B2 (en) | 2015-07-28 | 2020-03-10 | J&M Shuler Medical, Inc. | Sub-atmospheric wound therapy systems and methods |
US10682257B2 (en) | 2015-07-29 | 2020-06-16 | Evophancie Biotech Ltd | Biological fiber composite dressing |
EP3328414B1 (en) | 2015-07-31 | 2020-08-12 | Blue Blood Biotech Corp. | Composition for use in promoting wound healing |
US10639350B2 (en) | 2015-08-10 | 2020-05-05 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using CD24 |
KR101787192B1 (en) | 2015-08-12 | 2017-10-18 | 주식회사 제네웰 | Antimicrbacterial dressing material and method for preparing thereof |
EP3135304A1 (en) | 2015-08-26 | 2017-03-01 | Mölnlycke Health Care AB | Foamed silicone in wound care |
WO2017040074A1 (en) | 2015-08-31 | 2017-03-09 | 3M Innovative Properties Company | Negative pressure wound therapy dressings comprising (meth)acrylate pressure-sensitive adhesive with enhanced adhesion to wet surfaces |
WO2017052301A1 (en) | 2015-09-25 | 2017-03-30 | 롯데정밀화학 주식회사 | Composition for hydrogel sheet, hydrogel sheet manufactured therefrom, and method for manufacturing same |
JP6890583B2 (en) | 2015-09-30 | 2021-06-18 | スリーエム イノベイティブ プロパティズ カンパニー | Hydrogel composition bonded to a polymer substrate |
GB2543307B (en) | 2015-10-14 | 2020-12-09 | Selentus Science Ltd | Haemostatic device |
CN108472157B (en) | 2015-10-30 | 2024-05-28 | 先进敷料有限责任公司 | Tissue treatment device and method |
GB2544342B (en) | 2015-11-13 | 2020-06-03 | First Water Ltd | Compositions for application to wounds |
US10617784B2 (en) | 2015-11-13 | 2020-04-14 | 3M Innovative Properties Company | Anti-microbial articles and methods of using same |
US10568773B2 (en) | 2015-11-18 | 2020-02-25 | Kci Licensing, Inc. | Medical drapes and methods for reducing trauma on removal |
EP3669840B1 (en) | 2015-11-20 | 2022-12-28 | 3M Innovative Properties Company | Medical system with flexible fluid storage bridge |
GB201520990D0 (en) | 2015-11-27 | 2016-01-13 | Edixomed Ltd | Dressing system |
FR3044893B1 (en) | 2015-12-09 | 2018-05-18 | Emile Droche | DRESSING FOR SKIN CARE IN A WET MEDIUM |
US10575991B2 (en) | 2015-12-15 | 2020-03-03 | University Of Massachusetts | Negative pressure wound closure devices and methods |
CN108472160B (en) | 2015-12-30 | 2022-02-22 | 史密夫及内修公开有限公司 | Negative pressure wound therapy apparatus |
WO2017115146A1 (en) | 2015-12-30 | 2017-07-06 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
EP3511031B1 (en) | 2015-12-30 | 2023-05-03 | Paul Hartmann AG | Devices for controlling negative pressure wound therapy |
EP3400032B1 (en) | 2016-01-06 | 2020-03-18 | KCI Licensing, Inc. | System for the treatment of wounds with dressing having closed cells |
WO2017122224A1 (en) | 2016-01-12 | 2017-07-20 | Council Of Scientific & Industrial Research | A nanobiocomposite formulation for wound healing and a process for the preparation thereof |
DE102016000569B3 (en) | 2016-01-20 | 2017-06-22 | Lohmann & Rauscher Gmbh | Method for producing a film tube |
US10918770B2 (en) | 2016-02-12 | 2021-02-16 | Corning Incorporated | Vacuum assisted wound closure assembly and methods of irradiating a wound using the same |
FR3047901B1 (en) | 2016-02-22 | 2018-02-23 | Universite Pierre Et Marie Curie (Paris 6) | BIOMATERIAL COMPOSITIONS WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS |
CA3015997A1 (en) | 2016-03-01 | 2017-09-08 | Kci Licensing, Inc. | Drape for use with medical therapy systems |
KR101958014B1 (en) | 2016-03-14 | 2019-03-13 | 주식회사 엘지화학 | Preparation method of super absorbent polymer |
FR3048885A1 (en) | 2016-03-17 | 2017-09-22 | Bluestar Silicones France | SILICONE ADHESIVE GEL WITH SKIN |
US20200297892A1 (en) | 2016-03-18 | 2020-09-24 | Kci Usa, Inc. | Antimicrobial wound dressing |
KR101959547B1 (en) | 2016-03-25 | 2019-03-18 | 주식회사 엘지화학 | Preparation method for super absorbent polymer |
WO2017176849A1 (en) | 2016-04-05 | 2017-10-12 | Patrick Kenneth Powell | Wound therapy system |
GB201608099D0 (en) | 2016-05-09 | 2016-06-22 | Convatec Technologies Inc | Negative pressure wound dressing |
EP3246050A1 (en) | 2016-05-17 | 2017-11-22 | BSN medical GmbH | Wound or skin patch |
ES2900548T3 (en) | 2016-05-31 | 2022-03-17 | Octapharma Ag | Plasma-based films and methods for making and using the same |
US20200282100A1 (en) | 2016-06-01 | 2020-09-10 | 3-D Matrix, Ltd. | Hemostatic Dressings with Self-Assembling Peptide Hydrogels |
CN109640904A (en) | 2016-07-08 | 2019-04-16 | 康沃特克科技公司 | Fluid collection device |
TWI673056B (en) | 2016-07-22 | 2019-10-01 | 大江生醫股份有限公司 | Bacterium-containing hydrogel and method of making the same |
US10076552B2 (en) | 2016-08-09 | 2018-09-18 | DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. | Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof |
DE102016114819A1 (en) | 2016-08-10 | 2018-02-15 | Paul Hartmann Ag | Absorbent body for endoluminal negative pressure therapy |
US20190351092A1 (en) | 2016-08-10 | 2019-11-21 | Argentum Medical, Llc | Antimicrobial hydrogel dressings |
ES2833899T3 (en) | 2016-08-10 | 2021-06-16 | Adv Med Solutions Ltd | Wound dressing |
US20180056087A1 (en) | 2016-08-26 | 2018-03-01 | Adolfo Ribeiro | Wearable Micro-LED Healing Bandage |
TWI674903B (en) | 2016-09-26 | 2019-10-21 | 國立陽明大學 | Process for a preparation of the modified porcine plasma fibronectin for enhance wound healing |
IT201600096247A1 (en) | 2016-09-26 | 2018-03-26 | Emodial S R L | Polyurethane-based bandage and hydrogel comprising chlorhexidine |
US11111362B2 (en) | 2016-09-26 | 2021-09-07 | Becton, Dickinson And Company | Breathable films with microbial barrier properties |
WO2018067622A1 (en) | 2016-10-05 | 2018-04-12 | 3M Innovative Properties Company | Fibrinogen composition, method and wound articles |
US10293080B2 (en) | 2016-10-05 | 2019-05-21 | The Arizona Board Of Regents On Behalf Of Northern Arizona University | Ionic liquids that sterilize and prevent biofilm formation in skin wound healing devices |
GB2555584B (en) | 2016-10-28 | 2020-05-27 | Smith & Nephew | Multi-layered wound dressing and method of manufacture |
US20190246721A1 (en) | 2016-11-02 | 2019-08-15 | Conopco, Inc., D/B/A Unilever | Antiperspirant device and method |
US11617684B2 (en) | 2016-11-02 | 2023-04-04 | Smith & Nephew, Inc. | Wound closure devices |
WO2018089742A1 (en) | 2016-11-11 | 2018-05-17 | Avery Dennison Corporation | Rubber-based soft gel skin adhesives |
CN110072497B (en) | 2016-11-11 | 2020-08-11 | 3M创新有限公司 | Conformable wound dressing that can be trimmed |
WO2018094061A1 (en) | 2016-11-18 | 2018-05-24 | Kci Licensing, Inc. | Medical system and dressing for use under compression |
US10426874B2 (en) | 2016-12-02 | 2019-10-01 | Apex Medical Corp. | Wound management assembly and negative pressure wound therapy system |
WO2018102322A1 (en) | 2016-12-02 | 2018-06-07 | 3M Innovative Properties Company | Muscle or joint support article with bump |
US11446185B2 (en) | 2016-12-02 | 2022-09-20 | 3M Innovative Properties Company | Muscle or joint support article |
US10500104B2 (en) | 2016-12-06 | 2019-12-10 | Novomer, Inc. | Biodegradable sanitary articles with higher biobased content |
WO2018104937A1 (en) | 2016-12-06 | 2018-06-14 | Sami Shamoon College Of Engineering (R.A.) | Topical antimicrobial formulations containing monovalent copper ions and systems for generating monovalent copper ions |
WO2018107130A1 (en) | 2016-12-09 | 2018-06-14 | Sanvio,Inc. | Composition for treating wounds and other dermatological conditions |
WO2018108784A1 (en) | 2016-12-12 | 2018-06-21 | Smith & Nephew Plc | Wound dressing |
DK3335696T3 (en) | 2016-12-15 | 2020-03-16 | Upm Kymmene Corp | Process for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract |
EP3335695B1 (en) | 2016-12-15 | 2020-02-05 | UPM-Kymmene Corporation | A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose |
EP3335740B1 (en) | 2016-12-15 | 2024-07-24 | UPM-Kymmene Corporation | Medical hydrogel |
EP3338813B1 (en) | 2016-12-20 | 2020-01-29 | BSN Medical GmbH | Multi-layer wound care product with perforated release layer |
EP3401354B1 (en) | 2016-12-22 | 2020-04-08 | LG Chem, Ltd. | Super absorbent polymer manufacturing method and super absorbent polymer |
CA3048014A1 (en) | 2016-12-22 | 2018-06-28 | Applied Tissue Technologies Llc | Devices and methods for wound treatment |
EP3558188A4 (en) | 2016-12-23 | 2020-06-17 | Calgon Carbon Corporation | Activated carbon composite wound dressing |
DE102016125579A1 (en) | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Hydrous hydrogel composition comprising elemental silver particles |
JP2020503131A (en) | 2016-12-28 | 2020-01-30 | シスタジェニックス ウンド マネージメント,リミテッドSystagenix Wound Management,Limited | Antibacterial wound dressing |
CN110099941A (en) | 2016-12-29 | 2019-08-06 | 爱乐康株式会社 | Foaming body and foaming compositions |
CN110267630B (en) | 2017-01-09 | 2021-12-28 | 3M创新知识产权公司 | Wound dressing layer for improved fluid removal |
TWI621453B (en) | 2017-01-13 | 2018-04-21 | 廈門聖慈醫療器材有限公司 | Suction disc |
CN108633253A (en) | 2017-01-19 | 2018-10-09 | 崔性铉 | The alleviation and treatment of the exudative skin disease of plasma proteins including atopic diseases pad |
EP3570798A1 (en) | 2017-01-23 | 2019-11-27 | Medela Holding AG | Porous wound insert for use in negative pressure therapy |
US20190365948A1 (en) | 2017-01-27 | 2019-12-05 | Aziyo Biologics, Inc. | Lyophilized placental composite sheet and uses thereof |
US11911249B2 (en) | 2017-02-06 | 2024-02-27 | Basf Se | Fluid-absorbent article |
AU2018220865B2 (en) | 2017-02-15 | 2023-03-16 | Smith & Nephew Asia Pacific Pte. Limited | Negative pressure wound therapy apparatuses and methods for using the same |
US11730853B2 (en) | 2017-02-16 | 2023-08-22 | Covestro Intellectual Property Gmbh & Co. Kg | Method for producing an adhesive-free wound contact composite material |
EP3585453B1 (en) | 2017-02-22 | 2023-05-17 | Cornell University | Mechanical vacuum dressing for mechanically managing, protecting and suctioning small incisional wounds |
US11141521B2 (en) | 2017-02-28 | 2021-10-12 | T.J.Smith And Nephew, Limited | Multiple dressing negative pressure wound therapy system |
CA3055250A1 (en) | 2017-03-03 | 2018-09-07 | Loma Linda University Health | Compositions and methods for promoting hemostasis |
AU2018229808B2 (en) | 2017-03-08 | 2024-04-11 | Smith & Nephew Plc | Negative pressure wound therapy device control in presence of fault condition |
EP3592400A4 (en) | 2017-03-09 | 2020-11-25 | Secretary, Department Of Biotechnology | A wound dressing for combined negative pressure and fluid delivery system |
WO2018162736A1 (en) | 2017-03-09 | 2018-09-13 | Smith & Nephew Plc | Wound dressing, patch member and method of sensing one or more wound parameters |
EP3378450A1 (en) | 2017-03-22 | 2018-09-26 | Mölnlycke Health Care AB | Method for manufacturing a wound dressing and a wound dressing |
EP3600461B1 (en) | 2017-03-29 | 2022-08-10 | 3M Innovative Properties Company | Hydrogel compositions bonded to polymeric substrates |
EP3606573B1 (en) | 2017-04-04 | 2021-08-25 | 3M Innovative Properties Company | Apparatuses, systems, and methods for the treatment of a tissue site with negative pressure and oxygen |
AU2018248422B2 (en) | 2017-04-04 | 2024-02-15 | Anti-Plasmin Technologies, Llc | Methods to enhance a non-surgical medical treatment |
KR101852718B1 (en) | 2017-04-04 | 2018-05-18 | 주식회사 제네웰 | Kit for pain reduction of incision site after surgical operation |
GB201800057D0 (en) | 2018-01-03 | 2018-02-14 | Smith & Nephew Inc | Component Positioning And stress Relief For Sensor Enabled Wound Dressings |
CN108721677B (en) | 2017-04-17 | 2021-11-19 | 广西美丽肤医疗器械有限公司 | Composite material |
WO2018195101A1 (en) | 2017-04-19 | 2018-10-25 | Smith & Nephew, Inc. | Negative pressure wound therapy canisters |
DE102017003826A1 (en) | 2017-04-20 | 2018-10-25 | Lohmann & Rauscher Gmbh | Wound treatment arrangement for the negative pressure therapy |
WO2018201257A1 (en) | 2017-05-04 | 2018-11-08 | Klox Technologies Inc. | Absorbent biophotonic devices and systems for wound healing |
EP3622973A4 (en) | 2017-05-10 | 2021-01-06 | Toray Industries, Inc. | Medical device |
JP7069219B2 (en) | 2017-05-10 | 2022-05-17 | メンリッケ・ヘルス・ケア・アーベー | Composite form in wound healing |
AU2018269113A1 (en) | 2017-05-15 | 2019-11-21 | Smith & Nephew Plc | Negative pressure wound therapy system using eulerian video magnification |
WO2018212849A1 (en) | 2017-05-16 | 2018-11-22 | Kci Licensing, Inc. | An absorbent negative-pressure dressing system for use with post-surgical breast wounds |
JP2020520781A (en) | 2017-05-17 | 2020-07-16 | ユービック インダストリー パートナーシップス インコーポレイテッドUvic Industry Partnerships Inc. | Wound dressing for wound monitoring and therapeutic drug delivery |
EP3634340A1 (en) | 2017-05-19 | 2020-04-15 | KCI USA, Inc. | Dressings for filtering wound fluids |
CN110785151A (en) | 2017-05-22 | 2020-02-11 | 凯希美国公司 | Elastically deformable wound dressing |
WO2018217620A1 (en) | 2017-05-22 | 2018-11-29 | Kci Usa, Inc. | Extensible dressings |
WO2018217619A1 (en) | 2017-05-22 | 2018-11-29 | Kci Usa, Inc. | Post-operative surgical wound dressing |
EP3409248B1 (en) | 2017-06-01 | 2019-11-06 | Absorbest AB | Wound dressing |
EP3634522A1 (en) | 2017-06-07 | 2020-04-15 | KCI Licensing, Inc. | Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment |
AU2018281102A1 (en) | 2017-06-07 | 2019-12-19 | 3M Innovative Properties Company | Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth |
EP3634333B1 (en) | 2017-06-07 | 2022-07-27 | 3M Innovative Properties Company | Peel and place dressing for thick exudate and instillation |
US11819387B2 (en) | 2017-06-07 | 2023-11-21 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
US11207217B2 (en) | 2017-06-07 | 2021-12-28 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
US20200085629A1 (en) | 2017-06-07 | 2020-03-19 | Kci Licensing, Inc. | Composite dressings with even expansion profiles for treatment of wounds using negative-pressure treatment |
CN110831552B (en) | 2017-06-07 | 2022-06-10 | 3M创新知识产权公司 | Multilayered wound filler with extended wear time |
JP2020523078A (en) | 2017-06-07 | 2020-08-06 | ケーシーアイ ライセンシング インコーポレイテッド | Composite dressing for promoting granulation and reducing maceration by negative pressure treatment |
KR20200016929A (en) | 2017-06-07 | 2020-02-17 | 케이씨아이 라이센싱 인코포레이티드 | Composite dressing for improving childcare and reducing smoke by using negative pressure treatment |
AU2018280059A1 (en) | 2017-06-07 | 2019-11-21 | Kci Usa, Inc. | Wound dressing with odor absorption and increased moisture vapor transmission |
US10695227B2 (en) | 2017-06-07 | 2020-06-30 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
EP3634339B1 (en) | 2017-06-07 | 2022-07-27 | 3M Innovative Properties Company | Peel and place dressing for negative-pressure therapy |
RU2019142454A (en) | 2017-06-07 | 2021-07-12 | Кейсиай ЛАЙСЕНСИНГ, ИНК. | Composite Dressings for Improved Granulation and Reduced Maceration for Negative Pressure Treatment |
US20210085839A1 (en) | 2017-06-08 | 2021-03-25 | Kci Licensing, Inc. | Negative-pressure therapy with oxygen |
EP3412319A1 (en) | 2017-06-09 | 2018-12-12 | Mölnlycke Health Care AB | Foam in wound treatment |
US20210145648A1 (en) | 2017-06-09 | 2021-05-20 | Kci Licensing, Inc. | Granulating Chronic Wound Dressing |
US20210161723A1 (en) | 2017-06-12 | 2021-06-03 | Kci Licensing, Inc. | Foamed and textured sintered polymer wound filler |
US11872110B2 (en) | 2017-06-13 | 2024-01-16 | Smith & Nephew Plc | Wound closure device and method of use |
WO2018231874A1 (en) | 2017-06-14 | 2018-12-20 | Smith & Nephew, Inc. | Control of wound closure and fluid removal management in wound therapy |
CA3065380A1 (en) | 2017-06-14 | 2018-12-20 | T.J.Smith & Nephew, Limited | Negative pressure wound therapy apparatus |
WO2018231878A1 (en) | 2017-06-14 | 2018-12-20 | Smith & Nephew, Inc. | Fluid removal management and control of wound closure in wound therapy |
WO2018236648A1 (en) | 2017-06-19 | 2018-12-27 | Kci Usa, Inc. | Wound dressing with saturation indicator |
CN110753512A (en) | 2017-06-23 | 2020-02-04 | 史密夫及内修公开有限公司 | Sensor positioning for performing sensor wound monitoring or treatment |
EP3644916A1 (en) | 2017-06-26 | 2020-05-06 | KCI USA, Inc. | Absorbent wound dressing that incorporates a novel wound fluid indicating system |
US10751212B2 (en) | 2017-06-26 | 2020-08-25 | Maryam Raza | Multilayer dressing device and method for preventing and treating pressure ulcers and chronic wounds |
DE102017006025A1 (en) | 2017-06-27 | 2018-12-27 | Carl Freudenberg Kg | Hydrogel-forming multicomponent fiber |
EP3644914A1 (en) | 2017-06-30 | 2020-05-06 | T J Smith & Nephew Limited | Negative pressure wound therapy apparatus |
EP3648810A1 (en) | 2017-07-07 | 2020-05-13 | Smith & Nephew plc | Wound therapy system and dressing for delivering oxygen to a wound |
GB201711183D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Antimicrobial or wound care materials, devices and uses |
GB201711181D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Polymer foam material, device and use |
FR3068974B1 (en) | 2017-07-12 | 2019-08-02 | Urgo Recherche Innovation Et Developpement | DRESSING FOR THE CONTROLLED AND PROLONGED DELIVERY OF ASSETS |
GB201711179D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Wound care materials, devices and uses |
FR3068975B1 (en) | 2017-07-12 | 2020-07-17 | Urgo Recherche Innovation Et Developpement | COMPOSITION FOR INTERFACE DRESSING |
EP3655050B1 (en) | 2017-07-21 | 2024-01-17 | Speed Care Mineral GmbH | New kind of wound dressing for haemostasis |
GB201804502D0 (en) | 2018-03-21 | 2018-05-02 | Smith & Nephew | Biocompatible encapsulation and component stress relief for sensor enabled negative pressure wound therapy dressings |
EP3659631B1 (en) | 2017-07-26 | 2023-08-30 | Youreh Co., Ltd. | Wound dressing comprising hyaluronic acid-calcium and polylysine and manufacturing method therefor |
GB201712165D0 (en) | 2017-07-28 | 2017-09-13 | Smith & Nephew | Wound dressing and method of manufacture |
US10780201B2 (en) | 2017-07-29 | 2020-09-22 | Edward D. Lin | Control apparatus and related methods for wound therapy delivery |
US10729826B2 (en) | 2017-07-29 | 2020-08-04 | Edward D. Lin | Wound cover apparatus and related methods of use |
EP4445922A2 (en) | 2017-07-31 | 2024-10-16 | KCI USA, Inc. | Bioresorbable dressing with structural support |
WO2019028057A1 (en) | 2017-08-02 | 2019-02-07 | Kci Licensing, Inc. | Systems and methods for wound debridement |
US11285048B2 (en) | 2017-08-02 | 2022-03-29 | Kci Licensing, Inc. | Multi-layer compartment dressing and negative-pressure treatment method |
DE102017117828A1 (en) | 2017-08-07 | 2019-02-07 | Ivf Hartmann Ag | Bandage, in particular compression bandage |
US11590030B2 (en) | 2017-08-07 | 2023-02-28 | Smith & Nephew Plc | Wound closure device with protective layer and method of use |
US11202849B2 (en) | 2017-08-09 | 2021-12-21 | Toray Industries, Inc. | Medical device and method for manufacturing the same |
SG11202000913XA (en) | 2017-08-10 | 2020-02-27 | Smith & Nephew | Positioning of sensors for sensor enabled wound monitoring or therapy |
WO2019040328A1 (en) | 2017-08-22 | 2019-02-28 | Kci Licensing, Inc. | In-line wound fluid sampling systems and methods for use with negative pressure wound therapy |
GB201713511D0 (en) | 2017-08-23 | 2017-10-04 | Scapa Uk Ltd | Wound dressing |
EP3672541A4 (en) | 2017-08-23 | 2021-06-09 | Cor Medical Ventures LLC | Post-operative surgical site wound treatment and method for device removal |
GB2565823A (en) | 2017-08-24 | 2019-02-27 | Xiros Ltd | Psyllium based moisture absorbent material |
EP3672655B1 (en) | 2017-08-24 | 2022-01-19 | KCI USA, Inc. | Biomaterial and methods of making and using said biomaterial |
US11246756B2 (en) | 2017-08-24 | 2022-02-15 | The United States Of America, As Represented By The Secretary Of Agriculture | Healthcare textiles |
WO2019050855A1 (en) | 2017-09-05 | 2019-03-14 | Kci Licensing, Inc. | Systems and methods for mitigating premature light deactivation of light deactivated adhesive drapes |
JP2020532378A (en) | 2017-09-05 | 2020-11-12 | ケーシーアイ ライセンシング インコーポレイテッド | Systems and methods that use a filtering layer to reduce the premature photoinactivation of photoinactivated adhesive drapes |
US11759144B2 (en) | 2017-09-10 | 2023-09-19 | Smith & Nephew Plc | Systems and methods for inspection of encapsulation and components in sensor equipped wound dressings |
GB201718070D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
WO2019053101A1 (en) | 2017-09-13 | 2019-03-21 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11547789B2 (en) | 2017-09-14 | 2023-01-10 | Kci Licensing, Inc. | Oxygen therapy with fluid removal |
CN111093721A (en) | 2017-09-15 | 2020-05-01 | 巴德阿克塞斯系统股份有限公司 | Antimicrobial dressing with liner for medical devices |
US12004926B2 (en) | 2017-09-18 | 2024-06-11 | Kci Licensing, Inc. | Wound dressings and systems with remote oxygen generation for topical wound therapy and related methods |
US11547611B2 (en) | 2017-09-22 | 2023-01-10 | Kci Licensing, Inc. | Wound dressings and systems with high-flow therapeutic gas sources for topical wound therapy and related methods |
IL254636A0 (en) | 2017-09-24 | 2017-11-30 | Reddress Ltd | Assembly and method for the preparation of a wound dressing |
IL254644B (en) | 2017-09-24 | 2021-06-30 | Reddress Ltd | Wound dressing device, assembly and method |
GB2566951A (en) | 2017-09-27 | 2019-04-03 | Brightwake Ltd | Compositions for wound treatment |
EP3687467B1 (en) | 2017-09-29 | 2022-02-23 | 3M Innovative Properties Company | Dressing exhibiting low tissue ingrowth and negative-pressure treatment method |
CN111200999A (en) | 2017-10-09 | 2020-05-26 | 3M创新有限公司 | Fixation dressing with conformable border |
GB201716986D0 (en) | 2017-10-16 | 2017-11-29 | Matoke Holdings Ltd | Antimicrobial compositions |
CN111491666B (en) | 2017-10-20 | 2021-09-07 | 水凝胶欧洲事务所 | Topical composition for treating burns |
WO2019083726A1 (en) | 2017-10-23 | 2019-05-02 | Kci Licensing, Inc. | Wound dressing for use with anti-bacterial material |
WO2019083607A1 (en) | 2017-10-23 | 2019-05-02 | Kci Licensing, Inc. | High-density evaporative bridge dressing |
CN115645640A (en) | 2017-10-23 | 2023-01-31 | 3M创新知识产权公司 | Regional management of tissue sites on joints |
US11432967B2 (en) | 2017-10-23 | 2022-09-06 | Kci Licensing, Inc. | Fluid bridge for simultaneous application of negative pressure to multiple tissue sites |
AU2018354152B2 (en) | 2017-10-23 | 2024-02-29 | Solventum Intellectual Properties Company | Low profile distribution components for wound therapy |
CN111447901A (en) | 2017-10-24 | 2020-07-24 | 凯希特许有限公司 | Debridement wound dressing and system for using same |
US11969317B2 (en) | 2017-10-26 | 2024-04-30 | 3M Innovative Properties Company | Wound dressing with welded elastic structure |
WO2019082023A1 (en) | 2017-10-26 | 2019-05-02 | 3M Innovative Properties Company | Composition containing a silicone-based adhesive and cellulose nanocrystals, and methods and articles |
WO2019083868A1 (en) | 2017-10-26 | 2019-05-02 | Kcl Licensing, Inc. | Manifolding apparatus or dressing exhibiting low tissue ingrowth and negative-pressure treatment method |
KR102566942B1 (en) | 2017-10-27 | 2023-08-14 | 주식회사 엘지화학 | Preparation method of super absorbent polymer |
EP4385535A3 (en) | 2017-10-27 | 2024-08-21 | Solventum Intellectual Properties Company | Contoured foam dressing shaped for providing negative pressure to incisions in the breast |
US11400202B2 (en) | 2017-10-30 | 2022-08-02 | Kci Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with pressure delivery indication |
WO2019089856A1 (en) | 2017-10-31 | 2019-05-09 | InMEDBio, LLC | Absorbent, breathable and pathogen blocking/killing wound care dressing and fabrication thereof |
GB201718054D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Sterilization of integrated negative pressure wound treatment apparatuses and sterilization methods |
EP3703632B1 (en) | 2017-11-01 | 2024-04-03 | Smith & Nephew plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB201718014D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Dressing for negative pressure wound therapy with filter |
IL255404B (en) | 2017-11-02 | 2018-10-31 | Technion Res & Dev Foundation | Hipe-templated zwitterionic hydrogels, process of preparation and uses thereof |
US11850122B2 (en) | 2017-11-02 | 2023-12-26 | 3M Innovative Properties Company | Wound dressing with humidity colorimeter sensor |
US11877910B2 (en) | 2017-11-03 | 2024-01-23 | Systagenix Wound Management, Limited | Nutrient-enriched dressing |
WO2019089266A1 (en) | 2017-11-03 | 2019-05-09 | Kci Licensing, Inc. | Extended wear-time dressing |
GB2568101B (en) | 2017-11-06 | 2022-09-07 | Brightwake Ltd | Antimicrobial dressing |
EP3706689A4 (en) | 2017-11-08 | 2021-12-01 | University Of Massachusetts | Post-operative hybrid dressing to optimize skin-grafting procedures in reconstructive surgery |
US20210177661A1 (en) | 2017-11-09 | 2021-06-17 | Kci Licensing, Inc. | Multi-module dressing and therapy methods |
WO2019094923A1 (en) | 2017-11-13 | 2019-05-16 | Kci Licensing, Inc. | Light-responsive pressure sensitive adhesives for wound dressings |
CN107899061A (en) | 2017-11-13 | 2018-04-13 | 广东泰宝医疗科技股份有限公司 | A kind of alginates wound repair dressing and preparation method thereof |
US11559438B2 (en) | 2017-11-15 | 2023-01-24 | Smith & Nephew Plc | Integrated sensor enabled wound monitoring and/or therapy dressings and systems |
EP3720518B1 (en) | 2017-12-06 | 2024-09-04 | Cornell University | Manually-operated negative pressure wound therapy (npwt) bandage with improved pump efficiency, automatic pressure indicator and automatic pressure limiter |
WO2019113091A1 (en) | 2017-12-06 | 2019-06-13 | Kci Licensing, Inc. | Wound dressing with negative pressure retaining valve |
NZ765192A (en) | 2017-12-11 | 2024-07-26 | Animal Ethics Pty Ltd | Wound dressing |
EP3498242A1 (en) | 2017-12-15 | 2019-06-19 | Mölnlycke Health Care AB | Medical dressing |
IL256405A (en) | 2017-12-19 | 2018-01-31 | Omrix Biopharmaceuticals Ltd | Wound dressing and a method for producing the same |
WO2019125962A1 (en) | 2017-12-20 | 2019-06-27 | Kci Licensing, Inc. | Wound dressing for the harvesting of superficial epidermal grafts |
US20200337904A1 (en) | 2017-12-20 | 2020-10-29 | Systagenix Wound Management, Limited | Dressing including dehydrated placental tissue for wound healing |
DE102017130893A1 (en) | 2017-12-21 | 2019-06-27 | Paul Hartmann Ag | pH regulating wound dressing |
WO2019134169A1 (en) | 2018-01-08 | 2019-07-11 | 万绵水 | Connecting device for wound protection dressing, and wound protection dressing |
US11877912B2 (en) | 2018-01-09 | 2024-01-23 | 3M Innovative Properties Company | Systems and methods for coupling a wearable therapy system to a dressing |
KR102565968B1 (en) | 2018-03-26 | 2023-08-09 | 디로얄 인더스트리즈, 인코퍼레이티드 | Multi Lumen Bridge for Negative Pressure Wound Care System |
US20190298882A1 (en) | 2018-03-27 | 2019-10-03 | Kevin M. Nelson | Hydrogel bandage |
EP4331481A3 (en) | 2018-03-29 | 2024-04-03 | 3M Innovative Properties Co. | Wound therapy system with wound volume estimation |
EP3773383A1 (en) | 2018-03-30 | 2021-02-17 | 3M Innovative Properties Company | An absorbent dressing incorporating ph wound condition indication |
GB201805584D0 (en) | 2018-04-05 | 2018-05-23 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB2572642B (en) | 2018-04-06 | 2021-03-31 | Pellis Care Ltd | Treatment of diabetic foot ulcers |
US11040127B2 (en) | 2018-04-09 | 2021-06-22 | Kci Licensing, Inc. | Abdominal dressing with mechanism for fascial closure |
US20210379273A1 (en) | 2018-04-10 | 2021-12-09 | Kci Licensing, Inc. | Bridge dressing with fluid management |
BR102018007306A2 (en) | 2018-04-11 | 2019-10-29 | Maria Cristina De Paula Mesquita | specific shape adhesive tape / plate making process / silicone dressing |
EP3773384B1 (en) | 2018-04-12 | 2024-07-17 | Solventum Intellectual Properties Company | Cutting template for a negative pressure wound therapy drape |
US11896464B2 (en) | 2018-04-13 | 2024-02-13 | Kci Licensing, Inc. | Method to dynamically measure apposition and patient limb movement in a negative pressure closed incision dressing |
WO2019200035A1 (en) | 2018-04-13 | 2019-10-17 | Kci Licensing, Inc. | Npwt system with selectively controllable airflow |
US11406750B2 (en) | 2018-04-13 | 2022-08-09 | Kci Licensing, Inc. | Compression strain and negative pressure delivery indicator for a wound dressing |
WO2019199849A1 (en) | 2018-04-13 | 2019-10-17 | Kci Licensing, Inc. | Dressing bolster with area pressure indicator |
WO2019212825A2 (en) | 2018-05-03 | 2019-11-07 | Kci Licensing, Inc. | Negative pressure wound therapy system with detection of full absorbant dressing |
WO2019213609A1 (en) | 2018-05-04 | 2019-11-07 | Dry See Llc | Liquid detecting article and method of making same |
MA52575A (en) | 2018-05-08 | 2021-03-17 | Fidia Farm Spa | DRESSING FOR THE TREATMENT OF DAMAGED SKIN |
EP3569261B1 (en) | 2018-05-14 | 2024-04-03 | Paul Hartmann AG | Functional wound dressing |
EP3569210B1 (en) | 2018-05-15 | 2022-04-27 | The Procter & Gamble Company | Disposable absorbent articles |
US10898606B2 (en) | 2018-05-15 | 2021-01-26 | Legacy Research and Development Group, LLC | Self-fusing low density silicone |
EP3773782A4 (en) | 2018-05-16 | 2022-03-02 | Midwest Training and Development Services, LLC | Negative pressure wound apposition dressing system |
US20190351095A1 (en) | 2018-05-21 | 2019-11-21 | Milliken & Company | Wound care device having fluid transfer and adhesive properties |
US20190351094A1 (en) | 2018-05-21 | 2019-11-21 | Milliken & Company | Wound care device having fluid transfer and adhesive properties |
FR3082123B1 (en) | 2018-06-07 | 2020-10-16 | Urgo Rech Innovation Et Developpement | CELLULARIZED DRESSING AND ITS MANUFACTURING PROCESS |
NL2021186B1 (en) | 2018-06-26 | 2020-01-06 | Icap Holding B V | Intelligent cap for skin tissue treatment |
WO2020005536A1 (en) | 2018-06-27 | 2020-01-02 | Kci Licensing, Inc. | Wound dressing for wound volume estimation |
TWI693929B (en) | 2018-06-27 | 2020-05-21 | 南六企業股份有限公司 | Antibacterial wound dressing |
US11701264B2 (en) | 2018-06-27 | 2023-07-18 | Kci Licensing, Inc. | Wound therapy system with wound volume estimation using geometric approximation |
WO2020005577A1 (en) | 2018-06-28 | 2020-01-02 | Kci Licensing, Inc. | Distributed negative pressure wound therapy system incorporating an absorbent dressing and piezo-electric pump |
EP3813746A1 (en) | 2018-06-28 | 2021-05-05 | KCI Licensing, Inc. | Long-duration, deep wound filler with means to prevent granulation in-growth |
EP3813750B1 (en) | 2018-06-28 | 2022-03-02 | KCI Licensing, Inc. | Release liner with edge protection |
WO2020003067A2 (en) | 2018-06-28 | 2020-01-02 | Systagenix Wound Management, Limited | Multilayer absorbent dressing construction |
US11896462B2 (en) | 2018-06-28 | 2024-02-13 | 3M Innovative Properties Company | Highly conformable wound dressing |
US20200000640A1 (en) | 2018-06-29 | 2020-01-02 | Milliken & Company | Multi-Layer Wound Care Device Having Absorption and Fluid Transfer Properties |
CN112334162A (en) | 2018-07-04 | 2021-02-05 | 科洛普拉斯特公司 | Foam wound dressing comprising an antimicrobial agent |
GB201811449D0 (en) | 2018-07-12 | 2018-08-29 | Smith & Nephew | Apparatuses and methods for negative pressure wound therapy |
US20210268166A1 (en) | 2018-07-12 | 2021-09-02 | Kci Licensing, Inc. | Abdominal dressing with user selection of fascial closure force profile |
WO2020014310A1 (en) | 2018-07-13 | 2020-01-16 | Kci Licensing, Inc. | Advanced wound dressing with compression and increased total fluid handling |
EP3823684A1 (en) | 2018-07-16 | 2021-05-26 | KCI Licensing, Inc. | Fluid instillation apparatus for use with negative-pressure system incorporating wireless therapy monitoring |
CN112512469A (en) | 2018-07-18 | 2021-03-16 | 凯希特许有限公司 | Wound viewing dressing and customization kit |
CN112512468A (en) | 2018-07-30 | 2021-03-16 | 3M创新有限公司 | Antimicrobial foam articles and methods of making the same |
EP3829506B1 (en) | 2018-07-31 | 2023-12-20 | 3M Innovative Properties Company | Devices and methods for preventing localized pressure points in distribution components for tissue therapy |
US20200038252A1 (en) | 2018-07-31 | 2020-02-06 | Joseph Spiro | Tri-layered wound dressing and method therefor |
WO2020026144A1 (en) | 2018-08-01 | 2020-02-06 | Systagenix Wound Management, Limited | Dressing packaging with controlled hydration of fluid-activated dressing |
CN112512479B (en) | 2018-08-01 | 2024-10-01 | 3M创新知识产权公司 | Soft tissue treatment using negative pressure |
WO2020028514A1 (en) | 2018-08-03 | 2020-02-06 | Kci Licensing, Inc. | Flexible and conformable wound dressing with enhanced fluid absorption capability |
EP3829667B1 (en) | 2018-08-03 | 2024-05-08 | Solventum Intellectual Properties Company | Wound therapy system with wound volume estimation |
US20210161725A1 (en) | 2018-08-10 | 2021-06-03 | Kci Licensing, Inc. | Wound dressing system for management of fluids in a wound and methods for manufacturing same |
EP3836872A1 (en) | 2018-08-13 | 2021-06-23 | KCI Licensing, Inc. | Disruptive dressing for use with negative pressure and fluid instillation |
US20200046876A1 (en) | 2018-08-13 | 2020-02-13 | Chuang Sheng Medicine Equipment Co. Ltd. | Hydrogel surgical dressing product having a multi-dimensional flexible hydrophilic structure-linkage composite |
WO2020035811A1 (en) | 2018-08-17 | 2020-02-20 | 3M Innovative Properties Company | Wound dressing system |
US11938236B2 (en) | 2018-08-17 | 2024-03-26 | Seoul Viosys Co., Ltd. | Medical dressing |
US11364334B2 (en) | 2018-08-21 | 2022-06-21 | Kci Licensing, Inc. | System and method for utilizing pressure decay to determine available fluid capacity in a negative pressure dressing |
WO2020040917A1 (en) | 2018-08-21 | 2020-02-27 | Kci Licensing, Inc. | Dressing and system with improved total fluid handling |
EP3840795B1 (en) | 2018-08-24 | 2024-07-17 | Solventum Intellectual Properties Company | Methods of managing moisture when using a low profile wound connection conduit |
CA3110340A1 (en) | 2018-08-24 | 2020-02-27 | The United States Government As Represented By The Department Of Veterans Affairs | Devices, systems, and methods for remotely monitoring and treating wounds or wound infections |
WO2020043665A1 (en) | 2018-08-27 | 2020-03-05 | Claudia Eder | Antiseptic gel |
WO2020044237A1 (en) | 2018-08-27 | 2020-03-05 | Advamedica Inc. | Composite dressings, manufacturing methods and applications thereof |
US11752039B2 (en) | 2018-08-28 | 2023-09-12 | Systagenix Wound Management, Limited | Dressings for reduced tissue ingrowth |
US11007083B2 (en) | 2018-08-28 | 2021-05-18 | Aatru Medical, LLC | Dressing |
WO2020046589A1 (en) | 2018-08-30 | 2020-03-05 | Kci Licensing, Inc. | Electro-mechanical pump for negative-pressure treatment |
WO2020047255A1 (en) | 2018-08-31 | 2020-03-05 | Kci Licensing, Inc. | Cooling dressing for improved comfort |
WO2020051089A1 (en) | 2018-09-04 | 2020-03-12 | Kci Licensing, Inc. | Wound therapy device and kit |
WO2020049038A1 (en) | 2018-09-04 | 2020-03-12 | Lohmann & Rauscher Gmbh | Wound cleansing device |
WO2020051273A1 (en) | 2018-09-05 | 2020-03-12 | Kci Licensing, Inc. | Systems and methods for scheduling and controlling wound therapy |
US11471335B2 (en) | 2018-09-05 | 2022-10-18 | University Of South Carolina | Gel-within-gel wound dressing |
WO2020055945A1 (en) | 2018-09-12 | 2020-03-19 | Kci Licensing, Inc. | Negative pressure wound therapy systems and methods to indicate total fluid handling |
WO2020056182A1 (en) | 2018-09-12 | 2020-03-19 | Kci Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth |
CN112912117B (en) | 2018-09-12 | 2024-10-18 | 3M创新知识产权公司 | Wound treatment system employing instillation therapy and dynamic pressure control |
CN112912042A (en) | 2018-09-14 | 2021-06-04 | 凯希特许有限公司 | Differential collapse wound dressing |
EP4353274A3 (en) | 2018-09-17 | 2024-05-01 | Solventum Intellectual Properties Company | Negative pressure wound therapy system |
WO2020060918A1 (en) | 2018-09-17 | 2020-03-26 | Kci Licensing, Inc. | Absorbent negative pressure dressing |
US20200086017A1 (en) | 2018-09-19 | 2020-03-19 | Deroyal Industries, Inc. | Tubing connection system for negative pressure wound therapy |
US20200093646A1 (en) | 2018-09-20 | 2020-03-26 | Kci Licensing, Inc. | Super-absorbent, low trauma, advanced wound dressing |
WO2020065531A1 (en) | 2018-09-25 | 2020-04-02 | Systagenix Wound Management, Limited | Wound dressing compositions and uses thereof |
DE102018007692A1 (en) | 2018-09-30 | 2020-04-02 | Alexander Folwarzny | Wound dressing |
EP3632476A1 (en) | 2018-10-05 | 2020-04-08 | John J. Ryan (Sealing Products) Limited | Wound contact surface and method of manufacture |
US11432965B2 (en) | 2018-10-05 | 2022-09-06 | Deborah Kantor | Medical bandage for the head, a limb or a stump |
US11266538B2 (en) | 2018-10-07 | 2022-03-08 | Michael David Francis | Adhesive wound dressing |
PL3636233T3 (en) | 2018-10-12 | 2023-10-16 | Ivf Hartmann Ag | Wet wound dressing having an adhesive edge |
US20210346589A1 (en) | 2018-10-15 | 2021-11-11 | Kci Licensing, Inc. | Micro balloon-on-tube wound filler |
FR3087126A1 (en) | 2018-10-16 | 2020-04-17 | Jean Francois Van Cleef | COMPOSITE WOUND MOLDING PROTECTION DEVICE |
CN112955100A (en) | 2018-10-17 | 2021-06-11 | 凯希特许有限公司 | Peel-off and placement dressing with closed cell contact layer |
EP3866741A1 (en) | 2018-10-17 | 2021-08-25 | KCI Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with reduce tissue in-growth |
US20210338486A1 (en) | 2018-10-18 | 2021-11-04 | T.J.Smith And Nephew,Limited | Tissue treatment device |
GB201817052D0 (en) | 2018-10-19 | 2018-12-05 | Smith & Nephew | Tissue treatment device |
US11839528B2 (en) | 2018-10-22 | 2023-12-12 | Medline Industries, Lp | Drypad with rapid absorption and liquid removal |
EP3643328A1 (en) | 2018-10-24 | 2020-04-29 | Paul Hartmann AG | Ph-triggered diagnostic wound dressing |
EP3643331A1 (en) | 2018-10-24 | 2020-04-29 | Paul Hartmann AG | Ph-triggered therapeutic wound dressing |
US20200129339A1 (en) | 2018-10-24 | 2020-04-30 | Hydrofera, Llc | Sterilization of medical devices with enhanced antimicrobial properties |
EP3643330A1 (en) | 2018-10-24 | 2020-04-29 | Paul Hartmann AG | Ph-triggered buffered wound dressing |
WO2020092598A1 (en) | 2018-10-30 | 2020-05-07 | Kci Licensing, Inc. | Ease of use dressing with integrated pouch and release liner |
US11517644B2 (en) | 2018-11-02 | 2022-12-06 | Covalon Technologies Inc. | Foam compositions, foam matrices and methods |
JP2022506831A (en) | 2018-11-08 | 2022-01-17 | ケーシーアイ ライセンシング インコーポレイテッド | Wound dressing with semi-rigid support for enhanced destruction using perforated dressings and negative pressure wound therapy |
EP3876886B1 (en) | 2018-11-08 | 2023-09-27 | 3M Innovative Properties Company | Dressing with protruding layer allowing for cleansing of wound bed macro deformations |
CN113507910A (en) | 2018-11-09 | 2021-10-15 | 3M创新知识产权公司 | Hybrid adhesive tissue cover |
CN116370192A (en) | 2018-11-13 | 2023-07-04 | 3M创新知识产权公司 | Thin dispensing member for wound treatment |
GB2579211A (en) | 2018-11-23 | 2020-06-17 | Brightwake Ltd | Medical tube |
GB2579368B (en) | 2018-11-29 | 2022-11-09 | Nexa Medical Ltd | Wound-dressing conditioning device |
US20200179300A1 (en) | 2018-12-10 | 2020-06-11 | Joseph Urban | Topical Formulation Cures and Heals a Variety of Skin Conditions Including Ulcers, Decubitus Ulcers, Cancer, Abrasions and other Conditions and also accelerates the curing and healing of those Conditions |
GB2579800B (en) | 2018-12-13 | 2021-11-03 | Adv Med Solutions Ltd | Resilient wound dressing |
GB2579790B (en) | 2018-12-13 | 2022-10-05 | Adv Med Solutions Ltd | Ribbon wound dressing |
WO2020124038A1 (en) | 2018-12-13 | 2020-06-18 | University Of Massachusetts | Negative pressure wound closure devices and methods |
ES2969517T3 (en) | 2018-12-21 | 2024-05-21 | Hartmann Paul Ag | Super absorbent wound dressing with silicone layer in contact with the wound |
EP4424287A1 (en) | 2018-12-21 | 2024-09-04 | Paul Hartmann AG | Superabsorbent wound dressing with silicone wound contact layer |
EP3669838A1 (en) | 2018-12-21 | 2020-06-24 | Paul Hartmann S.A. | Array of absorbent dressings for the treatment of wounds |
WO2020136555A1 (en) | 2018-12-27 | 2020-07-02 | 3M Innovative Properties Company | Hot melt processable (meth)acrylate-based medical adhesives |
-
2011
- 2011-12-07 WO PCT/US2011/063781 patent/WO2012078781A1/en active Application Filing
- 2011-12-07 CN CN201180067100.0A patent/CN103347561B/en active Active
- 2011-12-07 EP EP11847022.8A patent/EP2648793B1/en active Active
- 2011-12-07 CA CA2819475A patent/CA2819475C/en active Active
- 2011-12-07 US US13/992,637 patent/US10207031B2/en active Active
- 2011-12-07 JP JP2013543318A patent/JP5965409B2/en active Active
-
2016
- 2016-04-22 JP JP2016086432A patent/JP6306082B2/en active Active
-
2018
- 2018-12-31 US US16/237,421 patent/US11116884B2/en active Active
-
2021
- 2021-08-10 US US17/398,552 patent/US20210369937A1/en not_active Abandoned
- 2021-08-11 US US17/399,271 patent/US20210369938A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200281519A1 (en) * | 2017-09-10 | 2020-09-10 | Smith & Nephew Plc | Systems and methods for inspection of encapsulation and components in sensor equipped wound dressings |
US11759144B2 (en) * | 2017-09-10 | 2023-09-19 | Smith & Nephew Plc | Systems and methods for inspection of encapsulation and components in sensor equipped wound dressings |
Also Published As
Publication number | Publication date |
---|---|
EP2648793A4 (en) | 2014-09-17 |
JP2014509875A (en) | 2014-04-24 |
JP6306082B2 (en) | 2018-04-04 |
EP2648793B1 (en) | 2020-03-11 |
JP2016182343A (en) | 2016-10-20 |
US20190134280A1 (en) | 2019-05-09 |
WO2012078781A1 (en) | 2012-06-14 |
CA2819475A1 (en) | 2012-06-14 |
US20210369938A1 (en) | 2021-12-02 |
CA2819475C (en) | 2019-02-12 |
US20140058344A1 (en) | 2014-02-27 |
US10207031B2 (en) | 2019-02-19 |
JP5965409B2 (en) | 2016-08-03 |
US11116884B2 (en) | 2021-09-14 |
EP2648793A1 (en) | 2013-10-16 |
CN103347561A (en) | 2013-10-09 |
CN103347561B (en) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210369937A1 (en) | Integrated system for assessing wound exudates | |
US11241525B2 (en) | Wound exudate monitor accessory | |
CN110868920B (en) | Wearable device with multi-modal diagnostics | |
US20170030758A1 (en) | Fluid output measurement device and method | |
EP3638104A1 (en) | Medical devices | |
JP2018528043A (en) | Medical waste fluid collection and disposal system | |
KR101634738B1 (en) | Wrist terminal for prevention of sudden death and system for prevention of sudden death using the same | |
US20160331876A1 (en) | Fluid collection and disposal system | |
KR20160109098A (en) | Biological information measurement Necklace | |
KR20210118438A (en) | Portable device and method for non-invasive blood glucose level estimation | |
KR20170017989A (en) | Biological information measurement Necklace | |
KR102693054B1 (en) | Dementia diagnosis system based on olfaction test and dementia diagnosis method based on olfaction test using the same | |
KR100743600B1 (en) | Bidet | |
JP2012013419A (en) | Urine sugar meter | |
WO2024000074A1 (en) | Systems and methods for predicting and detecting post-operative complications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CONVATEC TECHNOLOGIES INC., NEVADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOTH, LANDY;REEL/FRAME:064636/0605 Effective date: 20150316 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |